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Parkinson’s disease (PD) is the most common neurodegenerative movement disorder, and affects 
approximately 950 per 100,000 people in North America. The etiology of PD remains unknown, 
but a small percentage of affected individuals have heritable forms of the disease with known 
genetic causes. Study of the proteins encoded by these genes has provided tremendous insight 
into molecular pathways that underlie PD-associated neurodegeneration. Mutations in the gene 
encoding PTEN-induced kinase 1 (PINK1) have been identified as the cause of an autosomal, 
recessively inherited parkinsonism. PINK1 is a serine/threonine kinase, uniquely localized to 
both the cytosol and mitochondrion. The profound effect of PINK1 on mitochondrial 
homeostasis has been extensively investigated, but far less is understood about its function in the 
cytosol. This project aimed to identify cytosolic PINK1 interacting proteins and characterize the 
functional consequences of the association. Using an unbiased proteomic screen, valosin-
containing protein (VCP), an AAA+ ATPase, was identified as a PINK1 interactor. Upon 
discovery that the physical association does not require mitochondrial localization, the role of 
VCP in previously identified functions of the cytosolic pool of PINK1 was examined. These 
studies discovered a PINK1-VCP pathway that promotes neurite extension and complexity, and 
contributes to the maturation and maintenance of synapses. Further, PINK1 and VCP were 
shown to co-regulate autophagy and the accumulation of high molecular weight ubiquitination 
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products. These results indicate that the PINK1-VCP interaction plays a key role in dendritic 
arbor maintenance, synapse preservation, and autophagy regulation. These three processes are 
commonly impaired in sporadic and familial PD as well as other neurodegenerative diseases, 
indicating that treatments targeting components of the PINK1-VCP signaling hub may have 
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1.0  INTRODUCTION 
Nearly a decade ago, the serine/threonine kinase PTEN-induced kinase 1 (PINK1) was linked to 
a recessively inherited parkinsonism [1]. There is a growing body of evidence that PINK1 has 
unique functions depending on its subcellular localization. While accumulation of full-length 
PINK1 on the outer mitochondrial membrane (OMM) is a signal of mitochondrial dysfunction 
[2-5], the release of mitochondrial processed PINK1 into the cytosol of neuronal cells may act as 
a sensor of healthy mitochondria to promote differentiation [6] and survival [7, 8]. Considerable 
progress has been made in elucidating the mitochondrial functions of PINK1, but few studies 
have investigated its neurotrophic functions in the cytosol. As an early step in understanding the 
biology of cytosolic PINK1, this project aimed to identify cytosolic proteins that interact with 
PINK1 and contribute to its effects on dendrites. During the course of this work, valosin-
containing protein (VCP), an AAA+ ATPase molecular motor that remodels client proteins 
targeted for degradation, was identified as a PINK1 interactor. Further, VCP and neurofibromin-
1 (NF1), a VCP-interacting protein and key regulator of Ras and PKA signaling in neurons, 
expression is required for dendritic complexity promoted by PINK1. This study also discovered 
that collapsin response mediator protein 2 (CRMP2), a NF1-interacting protein and important 
regulator of neuritic, cytoskeletal dynamics and synaptic calcium influx, also associates with 
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PINK1. The interactions between these proteins, and their roles in promoting neuronal health 
will be explored in greater depth below.  
1.1 PARKINSON’S DISEASE 
Parkinson’s disease (PD) is the second most common neurodegenerative disorder, affecting 
approximately 950 per 100,000 people in North America [9]. James Parkinson first described the 
disorder in his 1817 work entitled “An Essay on Shaking Palsy”, identifying bradykinesia 
(slowness to initiate movement), resting tremor, rigidity, and postural instability as definitive 
features of the disease. These motor impairments arise from a loss of 50-60% of the 
dopaminergic neurons from the substantia nigra pars compacta (SNc) leading to an 80-90% 
reduction in striatal dopamine levels [10-12]. Proteinaceous cytoplasmic inclusions 
predominantly comprised of alpha-synuclein, ubiquitin, and neurofilament called Lewy Bodies 
are frequently found in the surviving neurons of the SNc [13]. Lewy pathology has also been 
observed in other neuronal populations, including the: cerebral cortex (especially limbic 
cortices), raphe nuclei and locus coeruleus of the pons, olfactory bulb, nucleus basalis of 
Meynert of the basal forebrain, and dorsal motor nucleus of the vagus of the medulla oblongata 
[14]. Neuronal injury or degeneration from these affected brain regions may contribute to the 
onset of non-motor symptoms of PD such as disrupted sleep/wake cycles, mood disturbances, 
hyposmia, cognitive impairment, and pain [15-17]. 
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1.1.1 Treatment of PD 
The dopamine precursor, L-3,4-dihydroxyphenylalanine (L-dopa) has been the gold standard 
treatment for PD for over four decades [18]. L-dopa is particularly efficacious at treating motor 
symptoms in early stages of the disease, but does nothing to prevent degeneration of the 
dopaminergic neurons of the SNc [19]. As a result, higher doses of the drug are needed to 
alleviate motor impairments. Eventually, even high doses are unable to manage these symptoms, 
and many patients develop dyskinesias or fluctuate between periods of symptom control and 
ineffective treatment. Dopamine receptor agonists or monoamine oxidase type B inhibitors have 
been used in early stages of PD to delay the L-dopa toxicity suspected to contribute to these long-
term complications [20-22], though a recent study suggests that postponing initiation of L-dopa 
treatment does not have a long-term benefit [21].  
Deep brain stimulation (DBS) of the globus pallidus or subthalamic nucleus is a fairly 
recent addition to the arsenal of PD therapeutics. This surgical intervention is designed to restore 
inhibitory input to the thalamus, which is dramatically reduced by degeneration of SNc neurons. 
DBS is typically offered while patients are still responsive to L-dopa. Despite the dramatic 
benefit for some patients, there are still significant drawbacks to this procedure [23]. Like 
dopamine replacement strategies, DBS does not prevent SNc neuronal loss and is primarily used 
to treat motor impairments. Additionally, there is some evidence of post-operative cognitive 
decline in a minority of patients, with onset of dementia being reported a few months after 
surgery [24]. Further, most individuals still require L-dopa to effectively manage their symptoms, 
albeit at lower, potentially less toxic doses [25].  
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1.1.2 Synaptic pathology in PD 
Dendritic spines are small protrusion along the dendritic membrane where synaptic input is 
concentrated and integrated. Mature dendritic spines are comprised of a spine head connected to 
the dendritic shaft through a narrow neck. Spine morphology is variable, and often divided into 
three subgroups: stubby, thin, and mushroom ([26]; Fig. 1). Long, thin protrusions along the 
dendritic shaft called filopodia are the precursor structure to mature spines [27, 28]. Numerous 
studies have elucidated an important correlation between spine morphology and synaptic 
function [29]. In general, increased synaptic strength is associated with a larger spine head 
volume. Thus, spine number and morphology alterations observed in neurodegenerative diseases, 
including Parkinson’s disease, may underlie dysfunctional neural circuits. 
Medium spiny neurons (MSNs), the majority neuronal population in the striatum, are 
densely studded with dendritic spines. Dopaminergic axons projecting from the SNc synapse on 
the neck of MSN spines, while glutamatergic neurons synapse on the spine head [30]. Loss of 
dendritic spines from MSNs has been widely observed in post-mortem tissue from PD patients 
[31-34]. It has been further demonstrated that the loss of dendritic spines in MSNs is tightly 
Figure 1: Spine morphology. Schematic representation of the thin filamentous dendritic spine 
precursor (filopodia) and examples of the various spine morphologies, including: thin, stubby, 
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linked to a reduction in complexity and size of the dendritic tree [32-35]. Additionally, reduction 
of spine number, decreased dendrite length, and dendritic beading of dopaminergic SNc neurons 
have been reported in a small cohort of PD patients [36]. Calcium dyshomeostasis is the 
prevailing hypothetical cause of these pathologies [34, 37], but more experimental evidence is 
needed to elucidate the underlying mechanism. 
1.1.3 Autophagy in PD 
Autophagy is highly conserved, catabolic process by which cytosolic components and organelles 
are targeted for degradation by the lysosome. Three types of autophagy have been defined based 
on their mechanism of sequestering cargo into lysosomes [38]. Proteins containing a consensus 
sequence recognized by heat shock cognate protein 70 (HSC70) are targeted for chaperone-
mediated autophagy. Cargo degraded by this mechanism is translocated into the lysosome 
through an interaction with the lysosome associated membrane protein 2a (LAMP2a). 
Microautophagy occurs when cytosolic components become engulfed by the lysosome through 
membrane involution, without intervening components. Macroautophagy, hereafter referred to as 
autophagy, is accomplished by engulfment of cargo into a double-membraned vesicle called an 
autophagosome that then fuses with a lysosome.  
Canonical autophagy is a complex process initiated upon inactivation of mammalian 
target of rapamycin (mTOR) [39]. This suppression results in the dephosphorylation and 
activation of complex comprised of UNC-like kinase 1 and 2 (ULK1/2), Autophagy like protein 
(Atg) 13, and FIP200. Following activation of the ULK complex, phagophore nucleation is 
initiated by recruitment of a membrane bound class III phosphatidylinositol 3-kinase (PtdIns3K) 
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complex to the phagophore assembly site [40]. This complex consisting of hVps34, Beclin-1, 
p150 and mutually exclusive binding partners Atg14L/AMBRA or UVRAG/Rubicon, generates 
phosphatidylinositol 3-phosphate (PI3P), the autophagosomal membrane lipid. Proposed sources 
of the autophagosome membrane include the: endoplasmic reticulum, Golgi apparatus, ER-Golgi 
intermediate compartment, recycling endosomes, and mitochondria-associated ER membranes 
[reviewed in [41]]. Two ubiquitin-like conjugation systems act to elongate and expand the 
phagophore. One arm of this process involves the conjugation of Atg5 to Atg12 through an Atg7 
and Atg10–dependent mechanism [42]. Atg5 and Atg12 are subsequently conjugated to Atg16L. 
Simultaneously, microtubule-associated protein light chain 3 (LC3) is conjugated to 
phosphatidylethanolamine by Atg7 and Atg3. These two pathways converge as the Atg5-Atg12-
Atg16L complex determines the membrane site for this LC3 lipidation. Following closure of the 
phagophore, the autophagosome is delivered to the lysosome by the microtubule motor dynein 
[43]. Auotphagosome maturation occurs when the membrane of the autophagosome fuses with 
endolysosomal compartments in a process mediated by a soluble NSF attachment protein 
(SNAP) receptor (SNARE) complex [44, 45].  
It is becoming increasingly clear that ubiquitin-dependent selective autophagy plays a 
key role in maintaining proteostasis. Ubiquitinated proteins in this pathway are recognized by 
ubiquitin binding domains of autophagy receptors that interact with autophagosomes through a 
LC3-interaction motif [46].  There is a growing body of evidence that protein aggregates are 
targeted for degradation by this process [47-50]. The autophagy receptors p62, optineurin 
(OPTN), neighbor of BRCA gene 1 (NBR1), toll-interacting protein (TOLLIP), and Cue5 can all 
mediate this mode of degradation, called aggrephagy [46].  
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Autophagy is implicated in a wide range of neurodegenerative diseases by histological 
analysis of post-mortem tissue. Nearly two decades ago, autophagosomes were observed in the 
SNc of PD patients, but not controls [51]. Shortly after, phospho-ERK1/2 was shown to 
accumulate on early autophagosomes in the SNc of individuals with Lewy body pathologies 
[52]. Basal autophagy is relatively efficient in neurons [53], suggesting that the observed 
accumulation of these structures arises from perturbed autophagy regulation in PD. It remains 
unclear whether this buildup is caused by hyperactivaton of autophagy, failure in autophagic 
flux, or a combination of these processes. Further, Lewy body formation is the pathological 
hallmark of PD [13]. Failure to clear these aggregates of ubiquitinated alpha-synuclein may point 
to a role for ubiquitin-dependent selective autophagy in PD, though evidence of enhanced or 
arrested aggrephagy in post-mortem PD brain has not yet been reported in the literature. 
1.2 PTEN-INDUCED KINASE 1 
The etiology of PD remains unknown, but a small percentage of affected individuals have 
heritable forms of the disease with known genetic causes. Mutations in the gene that encodes 
PTEN-induced kinase 1 (PINK1) are responsible for the second most common cause of 
autosomal recessive parkinsonism [54]. The early-onset parkinsonism caused by pathogenic 
PINK1 mutations was first identified in 2004 [55],  and is characterized clinically by earlier age 
of onset (range of 9-52 years), long disease duration, and sustained response to levodopa 
treatment [55-58]. Either reduced kinase activity or decreased protein stability has been reported 
for many of the identified mutations, suggesting that loss of PINK1 function is pathogenic.  
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1.2.1 Domains 
PINK1 is a ubiquitously expressed serine/threonine kinase with homology to the 
calcium/calmodulin family. Eleven conserved subdomains have been described within the kinase 
domain (Fig. 2; [59]) Subdomains I–IV orient and dock ATP, while subdomains VI–XI bind 
substrates to facilitate phosphotransfer to the targeted peptide. Two evolutionarily conserved 
autophosphorylation sites within the kinase domain have been shown to promote kinase activity 
[60]. Phosphorylation at Thr313, a residue that is pathogenic when mutated to methionine, also 
augments PINK1 kinase activity [61]. The kinase domain is flanked by a regulatory tail on the C-
terminus, a canonical, N-terminal mitochondrial targeting sequence (MTS), and putative 
transmembrane domain. 
Figure 2: Domain structure of PTEN-induced putative kinase 1 (PINK1) and homology of 
autophosphorylation sites. PINK1 is composed of a canonical N-terminal mitochondrial 
targeting sequence, putative transmembrane domain, serine/threonine kinase domain, and 
a C-terminal regulatory tail. Eleven conserved subdomains have been described within the 
kinase domain. Subdomains I–IV coordinate the orientation and docking of ATP, whereas 
the subdomains VI–XI are responsible for detection of target peptides and 
phosphotransfer. Two evolutionarily conserved, activating autophosphorylation sites 
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1.2.2 Mitochondrial import and processing  
Virtually all nuclear-encoded mitochondrial proteins are imported across the outer mitochondrial 
membrane (OMM) via the translocase of the outer membrane (TOM) complex [62]. Two 
receptor subunits of this complex, TOM20 and TOM22 recognize N-terminal mitochondrial 
targeting sequences (MTS) and initiate transport through the β-barrel pore of TOM40. Because 
PINK1 has a predicted N-terminal MTS, and complexes with TOM20, 22, and 40 on depolarized 
mitochondria [63], it is likely to be transported across the OMM through this pathway. However, 
a recent study found that PINK1 import can also occur in the absence of TOM40, through a 
mechanism that requires TOM70 [64]. TOM70 is a receptor subunit of the TOM complex that 
detects internal mitochondrial localization signals [62]. Cytosolic chaperones, including known 
PINK1 interactors, specifically interact with TOM70 to initiate transport of proteins that contain 
internal mitochondrial localization signals [65]. This finding provides insight into how trace 
amounts of PINK1 constructs lacking the predicted N-terminal MTS may be imported into the 
mitochondria as detected by protease protection assays [66, 67], and why interaction with 
CDC37/Hsp90 increases mitochondrial localization of PINK1 [68, 69]. Nevertheless, as only 
trace levels of overexpressed N-terminal deletions of PINK1 can be detected in mitochondria, the 
major pathway for PINK1 mitochondrial import likely occurs via the canonical MTS.  
The import and insertion of PINK1 into the inner mitochondrial membrane (IMM) is 
presumed to occur through the translocase of the inner membrane 23 (TIM23) complex in a 
process driven by ΔΨm. In general, proteins that are imported through the TOM complex are 
recognized by TIM50, which acts to guide the MTS through TIM23 [62]. Proteins destined for 
the IMM generally have a hydrophobic sequence following the MTS that acts as a stop transfer 
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signal. Upon sequence analysis of PINK1, a putative transmembrane domain that could act as a 
stop transfer signal has been identified [67, 70].  
The submitochondrial localization of PINK1, and its concurrent processing by 
mitochondrial proteases, occurs through a ΔΨm –dependent mechanism. An interference RNA 
(RNAi) screen suggested that the mitochondrial processing peptidase (MPP) processes PINK1, 
as it does many other mitochondrial proteins containing a N-terminal MTS [71]. Sim et al. have 
identified two conserved regions of PINK1, corresponding to amino acids 8-18 and 67-77 of 
human PINK1, that contain potential MPP cleavage motifs [70]. However, it has recently been 
shown that PINK1 processing was unaffected in isolated mitochondria treated with a divalent ion 
chelator to inhibit MPP [64, 66], and recombinant MPP did not cleave PINK1 in an in vitro assay 
[64]. The processing of the PINK1 precursor (~60 kDa band) into its ΔN1 form (~50 kDa) by 
presenilin-associated rhomboid-like protein (PARL) has been well characterized [71-74].  
This integral IMM protease cleaves PINK1 between the alanine-103 and phenylalanine-
104 residues, a site within the putative transmembrane domain [74]. The resultant product is 
likely targeted for proteasomal degradation [75], if not retained in the mitochondria, stabilized in 
a complex with other proteins or further processed by other peptidases. The protease responsible 
for producing the ΔN2 fragment (~45 kDa band) has not been identified. Following 
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Figure 3: Mitochondrial import of PINK1. In mitochondria with intact mitochondrial membrane 
potential, PINK1 is imported through the traditional TOM/TIM pathway before being processed by 
several mitochondrial proteases, including MPP and PARL. After processing, a portion of PINK1 
remains in the mitochondrial inner membrane space to promote mitochondrial complex I activity 
and contribute to the maintenance of mitochondrial membrane potential.  A pool of PINK1 is also 
released into the cytosol. This processed form of PINK1 is neuroprotective, but is rapidly degraded 
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1.2.3 PINK1 protects against apoptosis induced by parkinsonian injury   
Overexpression of PINK1 protects against a number of apoptotic stimuli with relevance to PD-
associated injury, including oxidative stress [76], proteasomal inhibition [55], mitochondrial 
depolarization [77], and ETC complex I inhibition [78]. Additionally, PINK1 depletion sensitizes 
cells to apoptosis induced by complex I inhibitors [78, 79] and mitochondrial depolarization 
[77]. PINK1-dependent phosphorylation of the mitochondrial chaperone TNF receptor-
associated protein 1 (TRAP1) [76], and anti-apoptotic protein Bcl-xl ([77], Fig. 4) have been 
shown to protect against cell death induced by oxidative stress and mitochondrial depolarization 
respectively. 
1.2.4 Mitochondrial functions of PINK1 
1.2.4.1 Energized mitochondria A growing body of evidence has made it increasingly clear that 
mitochondrial dysfunction is a key feature of PD pathogenesis. Compromised function of the 
electron transport chain (ETC) has been observed both in PD patient tissue, and genetic and toxin 
models of PD [80, 81]. The unique bioenergetic demands of neurons make maintenance of 
mitochondrial homeostasis crucial for their health and survival. Interestingly, impaired 
respiration, decreased mitochondrial membrane potential (ΔΨm) and reduced levels of ATP have 
also been reported in PINK1 deficient mammalian cells and animal models. A study employing 
mitochondria isolated from PINK1 knockout mouse embryonic fibroblasts (MEFs) found that a 
reduction in substrate oxidation, rather than proton leak, was responsible for the loss of ΔΨm 
[82].  This finding is consistent with reports of reduced ETC complex I [82-85] and II [82, 84, 
 
 
  13 
85] linked respiration in PINK1 deficient neurons and MEFs. However, increased opening of the 
mitochondrial permeability transition pore (mPTP) [85], and deficient activity of the 
mitochondrial Na+/Ca2+ exchanger (NCLX) [86, 87] have also been shown to contribute to loss 
of ΔΨm  and impaired respiration observed in PINK1 knockout cells. Further, PINK1 deficiency 
also affects substrate availability [86] and activity of aconitase [84], an enzymatic component of 
the tricarboxylic acid (TCA) cycle. While the mechanism underlying disruption of normal ETC 
function and ATP production caused by PINK1 deficiency remains unclear, Vitamin K2 is able to 
reverse ATP deficiencies in PINK1 null flies by its action as an ETC electron transporter [88]. 
This finding has not yet been validated in mammalian systems, but may suggest that improving 
the efficiency of the ETC is sufficient to overcome some bioenergetic consequences of the loss 
of PINK1 function.  
In addition to energy production, the mitochondria’s ability to buffer calcium is crucial to 
neuronal function. This is especially true of neurons that are exposed to frequent and sustained 
elevations in intracellular calcium concentration, such as the vulnerable populations in PD 
(reviewed in [89]). Cytosolic calcium is transported across the IMM into the matrix via the ΔΨm  
activity of the mitochondrial calcium uniporter (MCU) [90], and efflux of calcium from the 
mitochondria occurs through the Na+/Ca2+ exchanger (NCLX) [91]. Dysregulation of 
mitochondrial calcium handling has been reported in PINK1 deficient cells [85-87, 92].  
Elevated levels of calcium in the mitochondrial matrix have been observed in PINK1 deficient 
neuronal cells and MEFs [85, 86]. Gandhi et al. found that mitochondrial calcium extrusion in 
response to sodium was impaired in PINK1 deficient neurons, and reasoned that accumulation of 
calcium in the matrix was likely due to diminished efflux activity of NCLX [86]. 
Phosphorylation of NCLX by PKA at Ser258 has recently been shown to prevent this calcium 
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overload, preserve mitochondrial membrane potential, and promote neuronal survival of PINK1 
KO neurons [87]. Failure to extrude calcium may lead to the elevation in mitochondrial matrix 
calcium levels reported to increase susceptibility to opening of the mPTP and cell death in 
PINK1 knockout MEFs [85].  
1.2.4.2 Depolarized mitochondria In healthy cells, the processes of mitochondrial fission, 
fusion, and mitochondrial degradation by macroautophagy (mitophagy) are balanced in a 
dynamic equilibrium necessary for maintaining a healthy mitochondrial network. This is 
particularly important in neurons, which are dependent on oxidative phosphorylation and require 
extensive mitochondrial transport among dendrites and axons. Fusion events, mediated by the 
mitofusins (Mfn1 and 2) and optic atrophy protein (Opa1), allow for sharing of components. 
Fusion is often followed by fission events, mediated by Drp1, which allow for detachment of 
mitochondria from the network for transport as well as separation of damaged components for 
degradation [93]. A fraction of fission events may result in daughter mitochondria with different 
mitochondrial membrane potentials [94]; the daughter with the decreased ΔΨm is targeted for 
mitophagy [95]. When damaged or dysfunctional mitochondria are unable to repair themselves 
or undergo fusion, they are also targeted for mitophagy. However, the exact mechanism by 
which mitochondria are targeted to the autophagosome is an emerging area of research.  
In some model systems, PINK1 itself has been identified as a trigger for Parkin-
dependent mitochondrial degradation [96, 97]. Treatment of mammalian cells with the 
protonophore CCCP causes mitochondrial depolarization, which leads to cessation of import and 
intramitochondrial processing of PINK1 and results in accumulation of full-length PINK1 on the 
outer mitochondrial membrane (OMM). Parkin, an E3 ubiquitin ligase, is recruited to the 
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mitochondrion and facilitates its degradation by mitophagy [71, 98, 99]. Recently, it has been 
discovered that PINK1 phosphorylates both ubiquitin and parkin to promote parkin recruitment 
to the mitochondria in this experimental paradigm [4, 100, 101].  PINK1-activated parkin then 
builds ubiquitin chains on OMM proteins and recruits the autophagy receptors optineurin and 
NDP52 [102, 103]. 
As previously reviewed by Van Laar and Berman [104], the mitophagic pathway seems 
to vary by the bioenergetic state and morphology of the cell, and the type of stressor. The CCCP-
PINK-Parkin process occurs robustly in non-neuronal, glycolytic cells to result in complete or 
near-complete mitochondrial clearance. In neuronal and oxidative phosphorylation-dependent 
cells, CCCP treatment does not induce Parkin translocation [104] until after 24 hours of 
treatment [105]. Rotenone and 6-OHDA toxin models did not show accumulation of PINK or 
Parkin translocation, unlike CCCP [106]. The induction of mitophagy in PINK1-deficient 
animals and cells, dependent on increased superoxide and Drp-mediated fission, suggests 
additional mechanisms of PINK1-independent mitophagy [107]. This may involve 
externalization of cardiolipin (CL), an inner mitochondrial membrane phospholipid, to the 
mitochondrial surface, which was shown to occur in rotenone-treated cortical neurons. CL then 
interacts with microtubule-associated-protein-1-light chain-3 (LC3) on autophagic membranes to 
mediate mitophagy of the damaged mitochondrion [106]. 
PINK1 has been shown to form a complex with Miro, an outer mitochondrial membrane 
Rho GTPase, and Milton in Drosophila, proteins involved in trafficking of mitochondria [108]. 
PINK1, in cooperation with Parkin, downregulates Miro protein levels in Drosophila, leading to 
a decrease in mitochondrial trafficking in axons [109]. RNAi knockdown of Miro in CCCP-
treated HeLa cells leads to increased Parkin-mediated mitophagy [109]. As postulated by Van 
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Laar et al. (2013), the ability of PINK1/Parkin to decrease mitochondrial trafficking in axons 
could isolate the damaged mitochondria from the functional network, prevent the accumulation 
of damaged mitochondria in high-energy demand areas, such as axon terminals, and allow the 
mitochondria to be degraded [104].  
Figure 4: PINK1 substrates on depolarized mitochondria. Import of mitochondrial proteins is 
impaired in depolarized mitochondria, resulting in the accumulation of unprocessed PINK1 
on the mitochondrial surface. Localization of this species of PINK1 to the OMM of damaged 
mitochondria activates multiple signaling cascades. OMM-tethered PINK1 phosphorylates 
both ubiquitin and Parkin to promote mitochondrial recruitment of Parkin. PINK1 also 
regulates the phosphorylation and subsequent degradation of the mitochondrial fusion protein 
Mitofusin 2 and the mitochondrial transport adaptor Miro in this experimental paradigm. 
Loss of these proteins readies a mitochondrion for mitophagy by promoting mitochondrial 
fission and inactivating axonal trafficking. Following mitochondrial depolarization, PINK1 
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1.2.5 Role of PINK1 in neurite maintenance and synaptic function 
While a large body of literature describes the chemically induced accumulation of full-length 
PINK1 on the mitochondrial surface, far less is understood about the potential signaling 
function(s) of correctly processed PINK1. Given that healthy mitochondria process and release 
PINK1 to the cytosol, PINK1 could also serve as a sensor for mitochondrial function. In this 
capacity, correctly processed PINK1 may be released from healthy mitochondria to regulate 
other cellular functions.  
The cytosolic pool of PINK1 has been shown to regulate neurite morphology through a 
kinase–dependent mechanism [110]. Knockout of PINK1 in primary cortical and midbrain 
neurons reduces neurite length and complexity. Overexpression of either full length or ΔN-
PINK1 is able to rescue neurite morphology in these cells. A PINK1 construct targeted to the 
OMM, despite being able to partially reverse the effects of PINK1 deficiency on mitochondrial 
homeostasis, had no effect on neurite length. Although the mechanism has not been completely 
elucidated, PKA signaling amplifies the neurite outgrowth promoted by cytosolic PINK1 [110], 
suggesting that PINK1 and PKA signaling pathways converge to co-regulate neurite extension 
just as they do for mitochondrial calcium extrusion [87]. 
PINK1 rodent models have phenotypes that parallel those purportedly resulting from 
synaptic pathology in PD patients. Basal dopamine levels in the striatum and dopaminergic SNc 
neuron number are unaltered in young PINK1 KO and G309D-PINK1 knock-in (KI) mice (PD-
associated mutation) [111-113]. Despite the lack of SNc neurodegeneration, evoked release of 
catecholamines and long-term potentiation (LTP) is reduced in the striatum of 2-3 month old 
PINK1 KO mice [113]. Similarly, LTP failure that could be rescued by chemically induced 
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dopamine release was also reported in heterozygous PINK1 KO mice [114]. By 9 months, 
G309D-PINK1-KI mice have a reduction in basal levels of striatal dopamine that is exacerbated 
at 22-24 months [111].  Further, reduced expression of the D2 dopamine receptor has been 
reported in the striatum of PINK1 rats, a finding consistent with early-stage idiopathic PD [115]. 
These discoveries, when considered in combination with the role of PINK1 in neuronal 
morphology, point to a potential regulatory role of PINK1 in synaptic function.  
1.2.6 Role of PINK1 in autophagy regulation 
In addition to its widely investigated role in mitophagy, a small number of studies have 
implicated PINK1 in regulation of autophagy. PINK1 has been shown to interact with Beclin1 
and promote autophagosome accumulation [116]. Dissimilarly, overexpression of PINK1 
promotes resistance to LC3 puncta accrual induced by treatment with the PD-associated toxin 6-
hydroxydopamine in a neuronal cell line [117]. Further, increased LC3 lipidation has been 
reported in PINK1 deficient dopaminergic neuronal cell lines [117, 118] and the striatum of mice 
injected with PINK1 shRNA lentivirus [118]. PINK1 has also been shown to promote cell 
survival through mTORC2/Akt activation [8, 119], a pathway known to negatively regulate 
autophagy [120]. As discussed above, PINK1 has recently been shown to directly phosphorylate 
ubiquitin at Ser65 (p-Ser65-Ub) to promote autophagic clearance of mitochondria. Interestingly, 
cytoplasmic p-Ser65-Ub granules have been recently reported to surround Lewy bodies in the 
brain of idiopathic PD patients [121]. This finding implicates PINK1 in regulation of ubiquitin-









Figure 5: Dual functions of PINK1. In healthy mitochondria, PINK1 is imported through the 
TOM/TIM complexes and processed by several mitochondrial proteases before being released 
back into the cytosol (inset a). This cytosolic pool of PINK1 may serve as a signal to the cell that 
the integrity of its mitochondrial network remains intact. Processed PINK1 promotes complex I 
activity (inset b), regulates mitochondrial calcium homeostasis, suppresses 
autophagy/mitophagy, fosters neurite extension, enhances mitochondrial trafficking into 
dendrites, and activates survival and differentiation signaling pathways. When mitochondria lose 
their membrane potential, full length PINK1 accumulates on the OMM (inset a). As a result, 
axonal transport of mitochondria is arrested and the damaged mitochondrion becomes a target 
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1.3 VALOSIN CONTAINING PROTEIN IN NEURODEGENERATION 
Valosin-containing protein/p97 (VCP) belongs to a family of homohexameric AAA+ ATPases 
with diverse cellular functions [122]. Powered by ATP hydrolysis, VCP acts as a molecular 
motor to unfold ubiquitinated substrate proteins. This structural remodeling allows for substrates 
to be extracted from organellar membranes and isolated from binding partners. Many client 
proteins are targeted for autophagic or proteasomal degradation, but VCP also mediates 
membrane fusion and trafficking. Each monomer contains two ATPase domains, D1 and D2 that 
are assembled as stacked rings [123, 124]. Hexamerization of VCP requires the D1 domain, 
while the D2 domain is largely responsible for generating mechanical force [125]. VCP activity 
is targeted to distinct pathways by interaction with co-factors (reviewed in [126]). Over 40 VCP 
co-factors have been identified in the mammalian system, the majority of which bind to the N-
terminal domain.   
Missense mutations in the gene encoding VCP are the cause of a rare autosomal 
dominant disorder called inclusion body myopathy and Paget’s disease with frontotemporal 
dementia (IBMPFD), and have been linked to a small percentage of cases of familial 
amyotrophic lateral sclerosis [127-129]. These mutations are concentrated at the interface 
between the N and D1 domains, indicating that this site modulates an important function of VCP 
that is disrupted by pathogenic mutants.  Some, but not all, VCP pathogenic mutants augment the 
ATP hydrolytic activity of the D2 domain [130]. Arg155 is the amino acid most often 
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mutagenized in IBMPFD which is responsible for disease onset in approximately 50% of 
affected families [127]. Tissue degeneration begins earlier and occurs more rapidly in individuals 
harboring an Ala232 mutation, giving rise to a more severe clinical presentation. Thus, 
transgenic models of IBMPFD generally harbor one of these two mutations.  
Like many neurodegenerative diseases, accumulation of ubiquitinated protein aggregates 
has been observed in the brains of IBMPFD patients [131, 132]. This finding indicates that 
impaired protein degradation contributes to IBMPFD pathology. Proteasomal degradation seems 
to be largely preserved in cells expressing IBMPFD-associated VCP mutants [133, 134], though 
some endoplasmic reticulum-associated degradation clients may be affected [135, 136]. 
Conversely, expression of VCP pathogenic mutants results in a dramatic impairment of 
maturation of autophagosomes containing ubiquitinated proteins and aggregates [133, 137, 138]. 
Additionally, VCP has been detected in neuronal nuclear inclusion of multiple polyglutamine 
diseases, eosinophillic nuclear inclusions in the aged, and particularly relevant to this work, 
Lewy bodies of PD subjects [139]. This physical association with aggregates of varied 
composition suggests that VCP may be a component of a degradation pathway commonly 
perturbed in neurodegenerative disease.  
Abnormal mitochondrial morphology has been observed in two recently generated mouse 
models of IBMPFD. Enlarged mitochondria with disrupted cristae accumulate in the brain of 
homozygous and heterozygous VCP mutant (R155H) knock-in mice [140, 141]. Further, 
mitochondrial membrane potential is diminished and ATP production reduced in VCP deficient 
and VCP mutant expressing neuronal cells [142, 143]. Translocation of the yeast homolog of 
VCP, CDC48, with its co-factor VCP/Cdc48-associated mitochondrial stress-responsive 1 
(Vms1), preserves mitochondrial respiratory function in oxidatively stressed cells [144, 145]. 
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Therefore, failure to degrade VCP-Vms1 mitochondrial substrates may result in impaired 
mitochondrial function. There may be some redundancy in this pathway, as parkin, a PD-
associated protein, recruits VCP to chemically depolarized mitochondria [146, 147]. VCP-
dependent, proteasomal degradation of mitochondrial fusion proteins precedes parkin-mediated 
mitophagy in this experimental paradigm. The role of PINK1 in mitochondrial recruitment of 
VCP is less clear, but VCP overexpression ameliorates the mitochondrial morphology phenotype 
and protects against muscle degeneration in PINK1 knockdown flies [147].  
Formation and maintenance of appropriate synaptic connections is essential for brain 
function. Degeneration and dysfunction of neurons from the frontotemporal lobe give rise to 
cognitive impairments observed in approximately one-third of patients with IBMPFD [127]. 
These cognitive phenotypes are reflected in aged R155H- [148] and A232E-VCP [149] 
transgenic mice. Accumulation of aggregated proteins in the brains of these mice was 
simultaneously reported, though more mechanistic studies are needed to determine whether this 
is the primary insult leading to neurodegeneration. VCP is also a key regulator of dendritic 
pruning in flies through proteolytic [150] and non-proteolytic [151] mechanisms. Inactivation of 
VCP in this context caused a dramatic simplification of dendritic arbors, while a milder 
phenotype was observed in flies expressing R155H-VCP [150]. Recently, an elegant study 
described the role of VCP in regulation of dendritic spine density [152]. Through an interaction 
with neurofibromin-1 (NF1), a cytosolic protein that modulates Ras and adenylate cyclase (AC) 
activity, VCP promotes dendritic spinogenesis. Dendritic spine density is reduced in neurons 
expressing IBMPFD-disease associated VCP mutants that disrupt the association between NF1 
and VCP. Interestingly, expression of NF1 is unaffected by VCP knockdown either in the 
presence or absence of a proteasomal inhibitor. This suggests that NF1 is not targeted for 
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degradation through its association with VCP. Cumulatively, these studies indicate that VCP 
plays an important role in neuronal morphogenesis, and disruption of this function may directly 
contribute to dementia onset in IBMPFD patients.  
1.4 FUNCTIONS OF NEUROFIBROMIN 1 IN THE CENTRAL NERVOUS SYSTEM 
Neurofibromin 1 (NF1) is a large, multi-domain protein predominantly localized to the cytosol 
[153]. The 2818 amino acid protein is comprised of a cysteine-serine rich domain, tubulin-
binding domain, GTPase-activating protein related domain, Sec14 homology/leucine rich 
(phospholipid binding) domain, pleckstrin homology domain, and C-terminal domain. Mutations 
in NF1 cause neurofibromatosis type I, a prevalent autosomal, dominant tumor predisposition 
syndrome. Approximately 1 in 2,700 people are born with neurofibromastosis 1 [154]. Though 
the disease is fully penetrant, clinical presentation is widely varied in affected individuals [155]. 
Atypical skin pigmentation (café-au-lait macules, skin-fold freckling), and development of 
tumors in the peripheral nerve sheath (schwannomas, neurofibromas) and optical pathway are 
among the diagnostic criteria for neurofibromatosis-1 [153].  
Cognitive impairment is a common co-morbidity in neurofibromatosis patients [156, 
157]. Approximately 50% of children with neurofibromatosis-1 have formally diagnosed 
learning disabilities [158], a dramatic increase from the estimated 10% of the general population 
of children in the United States [159]. Inactivation of a single NF1 allele produces learning and 
memory phenotypes in mice, associated with impairment of LTP in the hippocampus [160]. 
Additionally, reduced cortical thickness has been observed in mice with conditional knockout of 
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NF1 in neuroglial progenitor cells (NF1-CreBLBP) [161]. Anatomical orientation and number of 
neurons in the cortex of NF1-CreBLBP mice are unaffected. Rather, the decrease in cortical 
thickness was attributed to simplified dendritic arbors and shortened neurites.  
Attention problems are also prevalent in individuals harboring pathogenic NF1 
mutations, with 38-50% meeting the diagnostic criteria for attention deficit disorder [158]. 
Learning and memory are impaired in heterozygous NF1 knockout mice, but they do not 
recapitulate attention deficits in these patients [162]. However, the attention phenotype is 
modeled in NF1 +/- mice with complete knock out of NF1 in astrocytes (NF1 +/-GFAP-CKO). The 
observed reduction in attentive behaviors coincided with reduced dopaminergic innervation to 
the striatum. Treatments that increase the availability of dopamine in the striatum ameliorated the 
attention abnormalities in NF1 +/-GFAP-CKO mice. Though dopamine depletion has not been 
reported in children with neurofibromatosis-1, attention deficit is effectively treated with 
dopamine reuptake inhibitors in these individuals [163]. Additionally, neurite length is reduced 
in dopaminergic neurons of the ventral midbrain from NF1 +/- mice [162]. Collectively, these 
studies in mouse models of neurofibromatosis 1 with disease-associated neurological symptoms 
suggests that NF1 plays an important role neuronal differentiation. In vitro studies have 
identified three mechanisms by which NF1 regulates neuronal morphology: inactivation of Ras, 
activation of AC/PKA signaling, and interaction with collapsin-response mediating protein 
(CRMP2).  
NF1 includes a Ras-GTPase activating protein (Ras-GAP) domain that is crucial to its 
activity as a tumor suppressor [153]. Finely tuned Ras activation in response to calcium influx is 
also necessary for appropriate synapse formation and maturation [164, 165]. Recently, NF1 was 
identified as the major Ras inactivator in dendritic spines [166]. Prolonged Ras activation 
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impairs formation and maintenance of functional excitatory synapses in NF1 deficient rat cortical 
neurons. This study complemented earlier work that identified a role for NF1 inactivation of Ras 
in neurotrophic factor induced neuronal differentiation of a neuroblastic cell line (PC-12) [167].   
Ras-overactivation has been observed in neurons derived from both the central nervous 
system (CNS) and peripheral nervous system (PNS), of NF1 +/- mice [168, 169]. Interestingly, 
NF1 haploinsufficiency does not affect neurite length of PNS neurons, but is dramatically 
reduced in CNS neurons. This neuritic phenotype in the CNS neurons correlates with a reduction 
in cyclic adenosine monophosphate (cAMP) production. Restoring PKA activation in these cells 
prevented the neurite shortening phenotype [169]. As described above, NF1 plays a role in the 
regulation of dendritic spinogenesis. While PKA activation alone is insufficient to promote 
spinogenesis [170, 171], it is required for dendritic filopodia formation induced by the synaptic 
protein syndecan-2 through its interaction with neurofibromin [170].   
Another synaptic protein, collapsin response mediator 2 (CRMP2), also interacts with 
NF1 in neuronal cells [172, 173]. This association requires cyclin-dependent kinase 5 (Cdk5) 
activity [173], a kinase known to phosphorylate CRMP2 at Ser522 [174, 175]. Impaired neurite 
outgrowth and accumulation of highly phosphorylated species of CRMP2 was observed 
following transient knockdown of NF1 in PC-12 neuroblastic cells [172]. Interestingly, NF1 
inhibits the phosphorylation of CRMP2 by Cdk5, GSK-3β, and Rho kinase. Expression of the 
GAP-related domain of NF1 or pharmacological inhibition of Cdk5, GSK-3β, and to a lesser 
extent RhoK reversed these neuritic phenotypes. It is unclear whether NF1 regulates upstream 
signaling cascades or simply acts as a physical barrier to inhibit CRMP2 phosphorylation by 
these kinases.     
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1.5 COLLAPSIN RESPONSE MEDIATOR PROTEIN 2 IN NEURONAL 
MORPHOGENESIS 
CRMP2 belongs to a family of five highly homologous, cytosolic proteins required for 
development and maintenance of CNS patterning. Of the five homologs, only CRMP2 is 
expressed at high levels in adult neurons and is particularly enriched in highly plastic regions of 
Figure 6: Regulation of neuronal morphogenesis by NF1. NF1 regulates neuronal morphology 
through three pathways: inactivation of Ras in dendritic spines to promote LTP, activation of AC 
activity to promote neurite outgrowth and dendritic filopodia formation. NF1 also binds CRMP2 
to inhibit hyperphosphorylation. CRMP2 induced neurite outgrowth is impaired by 
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the brain [176]. CRMP2 forms a quaternary complex as a homo- or hetero-tetramer with other 
members of the CRMP family [177]. By primary sequence analysis, CRMP2 is homologous to 
the enzyme dihydropyrimidinase [178]. Though CRMP2 enzymatic activity has not been 
described, divalent cations stabilize CRMP2 structure, just as they do in other members of the 
aminohydrolase family [179].  
The canonical function of CRMP2 is regulation of microtubule dynamics. 
Overexpression of CRMP2 results in neurite, particularly axonal, lengthening in culture [180, 
181]. This extension largely arises from the association of CRMP2 with the plus-end of 
microtubules. CRMP2 binding to tubulin promotes microtubule stability, leading to axonal 
elongation. Phosphorylation of CRMP2 at Thr509 and Thr514 by GSK3-β, which is preceded by 
a priming phosphorylation at Ser522 by Cdk5, disrupts this interaction. Perturbation of the 
CRMP2-tubulin interaction results in growth cone collapse and axonal retraction [174, 175, 182].  
CRMP2 also binds the microtubule motor proteins dynein [183, 184] and kinesin [185]. 
In neuronal cells, binding of CRMP2 to dynein impairs retrograde transport [183]. Studies 
performed in non-neuronal cells suggest that this transport retardation may allow for optimized 
delivery to the endocytic recycling pool [184]. Conversely, CRMP2 acts as an adaptor protein 
that facilitates anterograde transport through its interaction with kinesin light chain [182, 186]. 
Through this interaction, CRMP2 promotes delivery of the neurotrophin receptor tyrosine kinase 
(TrkB) [186], and specifically Rac1-associated protein-1/WASP family verprolin-homologous 
protein-1 (Sra/WAVE) complex [182] to the distal axon. CRMP2-mediated trafficking of these 
proteins fosters actin remodeling in the growth cone. Phosphorylation of CRMP2 by GSK3-β 
results in dissolution of the CRMP2-kinesin interaction, leading to actin filament disorganization 
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in the growth cone. These studies indicate that multiple pathways contribute to the regulation of 
neuronal morphology by CRMP2. 
  While CRMP2 functional studies have largely investigated its regulation of cytoskeletal 
remodeling, CRMP2 also interacts with key regulators of pre- and post-synaptic calcium influx 
and buffering. Calmodulin, an EF hand protein that is a crucial integrator of synaptic signaling 
[187], binds to CRMP2 in a calcium dependent manner. The association of CRMP2 with 
calmodulin inhibits its cleavage by calpain [188]. Inhibition of this cleavage promotes neuronal 
survival following N-methyl-D-aspartate (NMDA) excitotoxicity [189]. CRMP2 also binds to 
the NR2B subunit of the NMDA receptor to promote post-synaptic calcium entry [190]. 
Additionally, CRMP2 regulates pre-synaptic calcium influx [191] and neurotransmitter release 
[192] through its interaction with the neuronal (N)-type voltage-gated calcium channel 2.2 
(Cav2.2). Cav2.2 channels, act as the primary mediators of calcium induced neurotransmitter 
release in the axon terminals [193]. Phosphorylation of CRMP2 at Ser522 by Cdk5 promotes 
CRMP2-Cav2.2 binding and enhances Cav2.2 currents [194]. Mice with two alleles of an 
unphosphorylatable Ser522-CRMP2 mutant knocked in have severe deficits in spine density 
[195] and dendritic arbor patterning [196] of pyramidal neurons. Interestingly, neuronal activity 
suppresses GSK3-β activation in dendrites of cerebellar granule neurons [197]. This inhibition 
promotes dendritic outgrowth and complexity through a mechanism requiring CRMP2 
expression. Cumulatively, these studies indicate that CRMP2 also regulates synaptic calcium 
levels with potential implications for dendritic morphology and spinogenesis.  
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2.0  RATIONALE AND HYPOTHESIS 
The role of PINK1 in maintenance of mitochondrial homeostasis has been extensively 
investigated, but far less is understood about its function in the cytosol. Cytosolic PINK1 has 
regulates neurite length [110] and autophagy [117, 198], but the proteins with which it interacts 
to execute these functions are unknown. We identified VCP as a PINK1 interacting protein in a 
mass spectrometric screen of proteins that co-immunoprecipitated with PINK1. Most widely 
recognized as a key mediator of proteasomal degradation, VCP has also been implicated in 
autophagosome maturation and dendritic spinogenesis. Given these functional overlaps, I 
hypothesize that VCP and PINK1 act in concert to regulate autophagy and neuronal morphology. 
Further, I hypothesize that VCP and PINK1 have common downstream effectors, and 
perturbation of this signaling pathway would impair the ability of PINK1 to promote neurite 
outgrowth and suppress autophagy. The overarching aim of this work is to understand the 
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3.0  MATERIALS AND METHODS 
3.1 PINK1 KO MICE 
All animal studies were performed in accordance with protocols approved by the University of 
Pittsburgh Institutional Animal Care and Use Committee (IACUC). Dr. Chenjian Li kindly 
provided the PINK1 knockout (KO) mouse line, generated from C57/129_PINK1+/− ES cells. 
The colony is maintained in house as a heterozygous line on a C57/129 background, crossing 
two heterozygotes to produce WT and KO littermates. KNS-25 (5’-ATG AGA TGG AGG GGA 
GTC-3’), KNS-27 (5’-GGA AGG AGG CCA TGG AAA TTG-3’), and Neo3a (5’-GCA GCG 
CAT CGC CTT CTA TC-3’) primers are used to distinguish between WT, HET, and KO mice. 
3.2 CELL CULTURE 
3.2.1 Mouse primary neuron isolation 
Mouse embryos (E16) were aseptically removed from the embryonic sac of timed pregnant mice  
(Charles River Laboratories, Wilmington, MA, USA) and placed in ice-cold Dulbecco’s 
phosphate buffered saline (DPBS) (Gibco, Grand Island, NY, USA). A sterile scalpel was used 
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to decapitate the embryos and remove the brain. Subsequently, the meninges were gently peeled 
back from the brain and cortex dissected out. The cortex was then digested in 200 units of papain 
(Worthington Biochem. Corp. Lakewood, NJ, USA) in DPBS containing 2-3 grains of L-
cysteine (Sigma-Aldrich Corp., St. Louis, MO, USA), and 500 units of DNase (Sigma-Aldrich 
Corp., St. Louis, MO, USA). The digestion was stopped by addition of two-three drops of a 
solution containing 2.5 mg/mL ovomucoid trypsin inhibitor (Worthington Biochem. Corp. 
Lakewood, NJ, USA), 500 units DNase, and 2.5 mg/mL BSA (Fisher Scientific, Pittsburgh, PA, 
USA) in Neurobasal media (Gibco, Grand Island, NY, USA) buffered with 10 mM HEPES 
(BioWhittaker, Walkersville, MD, USA). Fire-polished glass Pasteur Pipets were then used to 
triturate the resulting digests into a single cell suspension before being centrifuged at 200 x g to 
pellet. Neuronal pellets were resuspended in Neurobasal media containing 2% B-27 (Invitrogen, 
Carlsbad, CA, USA), and 2 mM Glutamax (Invitrogen, Carlsbad, CA, USA) and plated on poly-
L-lysine coated 4-well Nunc LabTek 1.0 borosilicate glass chamber slides (VWR, Radnor, PA, 
USA). 
3.2.2 Human and mouse cell culture 
Human embryonic kidney 293 (HEK293) and human SH-SY5Y neuroblastoma cells were 
cultured in DMEM (Lonza Bioscience, Walkersville, MD, USA) with 10% fetal bovine serum 
(Fisher Scientific, Pittsburgh, PA, USA), 2 mM L-glutamine (BioWhittaker, Walkersville, MD, 
USA), and 10 mM HEPES.  Mouse cortical neurons were cultured in Neurobasal media 
containing 2% B-27, and 2 mM Glutamax. Every third day, half of the media was replaced with 
fresh Neurobasal medium. All cells were cultured at 37°C with 5% CO2.  
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PINK1-3xFLAG (#24) and empty vector (M14) stable cell lines were generated by 
transfecting pReceiver M14-PINK1-3xFLAG expression plasmid and the pReceiver M14 
backbone into parental SH-SY5Y cells using 0.1% Lipofectamine (Invitrogen, Carlsbad, CA, 
USA). Transfected cells were selected using 1 mg/mL G418 (Promega Life Sciences, Madison, 
WI, USA) in the DMEM media described above for 24 days. Individual colonies were expanded, 
and maintained in 150 mg/mL G418.  
3.2.3 Pharmacological treatments 
FCCP (Sigma-Aldrich Corp., St. Louis, MO, USA), DBeQ (Millipore, Billerica, MA, USA), 
H89 (Merck KGaA, Darmstadt, Germany) and MG132 (Millipore, Billerica, MA, USA), were 
prepared in dimethyl sulfoxide (DMSO) (Fisher Scientific, Pittsburgh, PA, USA). Cells were 
treated with DBeQ at concentrations indicated in the text for 4 hours, 10 µM FCCP for 2 hours, 
10 µM MG132 for 4 hours, or 250 nM H89 for 14 hours.  
3.2.4 Plasmids, siRNA, and transfections 
All plasmids used were prepared using the QIAGEN MaxiPrep Plasmid Purification kit (Qiagen, 
Venlo, Netherlands) according to the manufacturers’ protocol. The eGFPc-1, VCP-GFP, 
pcDNA3.1, and WT-PINK1-GFP plasmids were purchased from Clontech, Addgene, Invitrogen, 
and Genecopoeia respectively.  PLK0.5 and NF1shRNA-PLK0.5 plasmids were purchased from 
Sigma-Aldrich. ΔN-PINK1-GFP, OMM-PINK1-GFP, WT-LC3-HA, S12A-LC3-HA expression 
plasmids were previously generated by Dr. Ruben Dagda and Dr. Salvatore Cherra III while 
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members of Dr. Charleen Chu’s laboratory [110, 199]. Dr. Yi-Ping Hsueh kindly provided the 
FL-VCP-MYC, N-VCP-MYC, D1-VCP-MYC, D2-VCP-MYC, ND1-VCP-MYC, D1D2-VCP-
MYC, miRCTRL-GFP, and miRVCP-GFP plasmids. The OMM-GFP and PINK1-IRES-GFP 
plasmids were generous gifts from Dr. Stefan Strack and Dr. Dennis Selkoe respectively. PD-
associated PINK1-GFP mutants (E240K-, G309D-, L347P-, G409V-, L489P-) and IRES-GFP 
(by mutagenizing to a stop codon before PINK1 coding sequence) plasmids were generated 
using the QuikChange site-directed mutagenesis II kit. Small interfering RNA (siRNA) targeting 
human ATG7 and PINK1 were purchased from Dharmacon and Sigma-Aldrich respectively. 
Mouse NF1 siRNA was also purchased from Sigma Aldrich. 
All transfections were performed using Lipofectamine 2000 according to the 
manufacturers’ protocol. Briefly, the required volume of OptiMEM I (Gibco, Grand Island, NY, 
USA) was divided into two tubes. Plasmids and siRNA were incubated in one tube for five 
minutes. An OptiMEM and Lipofectamine 2000 mixture was then added to the tube containing 
plasmid and/or siRNA. Lipofectamine was allowed to complex with the plasmid/siRNA for 20 
minutes before being added drop wise to the media. When transfecting HEK293 or SH-SY5Y 
cells, DMEM media was changed immediately prior to transfection. Neurobasal medium was 
refreshed 12 hours following transfection of primary neurons. Lipofectamine 2000 was used at 
0.2%, .02%, and .01% in HEK293, SH-SY5Y, and primary neurons respectively. 
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3.3 BIOCHEMICAL ANALYSES 
3.3.1 Cell lysis 
Media was aspirated from HEK293 cells, and they were washed once in DPBS. HEK293 cells 
were then collected by scraping in lysis buffer (Miltenyi Biotec, Auburn, CA, USA) containing 
150 mM NaCl, 1% Triton. X-100, 50 mM Tris-HCl (pH 8.0) with a protease inhibitor cocktail 
(1:100) (Sigma-Aldrich Corp., St. Louis, MO, USA), 1 mM sodium orthovanadate (Sigma-
Aldrich Corp., St. Louis, MO, USA), and 2mM sodium pyrophosphate (Sigma-Aldrich Corp., St. 
Louis, MO, USA). SH-SY5Y cells were collected in scraping buffer containing 25mM HEPES 
(pH 7.5) (ResearchOrganics, Inc., Cleveland, OH, USA), 50mM NaCl (Fisher Scientific, 
Pittsburgh, PA, USA), 5mM EDTA (Fisher Scientific, Pittsburgh, PA, USA). Cells were pelleted 
by centrifugation at 5,000 x g for 5 minutes. All cells were incubated on ice in lysis buffer for 
one hour. Lysates were pelleted by centrifugation at 15,000 x g for 15 at 4°C. Supernatants were 
then collected, and protein concentration was quantified by bicinchoninic acid (BCA) assay 
(Thermo Scientific, Rockford, IL, USA).  
3.3.2 Immunoprecipitations 
GFP, HA, and DYKDDDDK (FLAG) immunoprecipitations (IPs) were performed using the 
µMACS Epitope Tag Protein Isolation Kit (Miltenyi Biotec, Auburn, CA, USA). Briefly, 50 µL 
of microbeads were incubated with 0.5-1.0 mg of protein for 30 minutes on ice. Samples were 
then applied to the µ column on the µMACS separator, and washed three times with 200 µLs of 
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Tris buffered saline (TBS). Microbeads were washed once with 20 mM Tris HCl (pH 7.5) before 
IP products were eluted in hot µMACS elution buffer (Miltenyi Biotec, Auburn, CA, USA) 
containing 50 mM Tris HCl (pH 6.8), 50 mM DTT, 1% SDS, 1 mM EDTA, 0.005% bromphenol 
blue, and 10% glycerol.  
IPs for endogenous proteins were performed by incubating 50 µL of Protein A agarose 
beads (Invitrogen, Carlsbad, CA, USA), 2 µg of indicated antibody, and 1 mg of cell lysate 
overnight at 4°C while rotating. Beads were collected by centrifugation at 4,500 x g for 2 
minutes, and washed four times for five minutes with TBS.  IP products were then eluted using 
hot µMACS elution buffer described above. 
3.3.3 Mass spectrometry for protein identification 
Forty-eight hours after plating, HEK293 cells were transfected with EGFPc-1 or WT-PINK1-
GFP. Two days following transfection, cells were harvested and GFP IPs performed as described 
above. IP products were briefly run into a stacking gel. Gel bands were excised and destained in 
100 mM ammonium bicarbonate. Proteins were reduced in 5 mM DTT in 100 mM ammonium 
bicarbonate at 60°C for 30 minutes. Samples were cooled to room temperature before being 
alkylated in 15 mM iodoacetamide in the dark for 30 minutes. Solution was removed, and gel 
plug washed for 20 minutes in 50% acetonitrile/100 mM ammonium bicarbonate. Gel band was 
then incubated overnight in 0.05 µg/µL trypsin in 100 mM ammonium bicarbonate at a 1:100 
enzyme to protein ratio. Digested peptides were extracted in 60% acetonitrile/0.1% 
trifluoroacetic acid before being lyophilized and resuspended in 5% formic acid.  
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An EASY-nLC II liquid chromatography system coupled to an Orbitrap Elite Mass 
Spectrometer was used to collect data. High-resolution peptide precursor measurements were 
made in the Orbitrap (R=60,000 at 400m/z) and low-resolution peptide fragment ion spectra 
were collected by collision-induced dissociation in a dual-linear ion trap. SEQUEST against a 
Uniprot-derived human protein database (downloaded 01/17/2011) amended with an entry for 
GFP was used to search data. Search parameters were: 10.0 ppm mass tolerance for peptide 
precursor measurements, 0.36 amu mass tolerance for fragmentation spectra, enzyme tolerance 
for trypsin, static modification of cysteine residues for carbamidomethylation (57.02 amu) and 
variable modifications on methionine oxidation (15.99amu). To enable analysis of “presence-
absence” scenarios, Log2 ratios were calculated for proteins identified by a minimum of two 
peptides by adding 0.5 to normalized spectral counts.  
3.3.4 Immunoblotting 
Equivalent amounts of protein were resolved by SDS-PAGE at 90 volts and transferred to 0.45 
µm PVDF membranes (Millipore, Billerica, MA, USA) using the Trans-Blot® SD Semi-dry 
Transfer Cell (Bio-Rad, Hercules, CA, USA). Membranes were incubated in 5% milk in PBS 
with 0.3% Tween 20 (PBST) (Fisher Scientific, Pittsburgh, PA, USA), for one hour at room 
temperature. Subsequently, blots were incubated in primary antibodies at indicated 
concentrations (Table 1) overnight at 4°C. Following three washes in PBST, membranes were 
incubated for one hour in horseradish peroxidase conjugated secondary antibodies diluted 1:5000 
in 5% milk in PBST at room temperature. Blots were then washed three times in PBST, 
developed using Luminata Western HRP Substrates (Millipore, Billerica, MA, USA) or 
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SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific, Rockford, IL, USA), 
and imaged using the LI-COR Odyssey Fc.  
Densitometric analysis was performed using the LI-COR ImageStudio Lite software. 
Chemiluminescent signal of the protein of interest was normalized to GAPDH or β-actin signal. 
As previously described, biological replicates were normalized by dividing the signal of each 
sample by the summated signal of each sample in that biological replicate [200]. 
 
Antigen Dilution Company 
β-Tubulin III 1:5,000 Abcam, Cambridge, MA, USA 
β-actin 1:5,000 Sigma-Aldrich Corp., St. Louis, MO, USA 
CRMP2 1:2,500 Abcam, Cambridge, MA, USA 
FLAG 1:2,000 Sigma-Aldrich Corp., St. Louis, MO, USA 
GAPDH 1:10,000 Abcam, Cambridge, MA, USA 
GFP 1:5,000 Invitrogen, Carlsbad, CA, USA 
LC3 1:1,000 Novus Biologicals, Littleton, CO, USA 
MYC 1:2,000 Cell Signaling Technology, Danvers, MA, USA 
NF1 1:1,000 Bethyl Laboratories, Montgomery, TX, USA 
PARP1 1:1,000 Cell Signaling Technology, Danvers, MA, USA 
PINK1 1:500 Novus Biologicals, Littleton, CO, USA 
pCRMP2 (Ser522) 1:1,000 ECM Biosciences, Versailles, KY, USA 
pLC3 (Ser12) 1:500 Abgent Inc., San Diego, CA, USA 
PSD95 1:500 Millipore, Billerica, MA, USA 
SYN 1:1,000 Chemicon, Temecula CA, USA 
Ub 1:1,000 Santa Cruz Biotechnology, Santa Cruz, CA, USA 
VCP 1:2,000 Thermo Scientific, Rockford, IL, USA 
VGLUT1 1:500 UC Davis/NIH NeuroMab Facility, Davis, CA, USA 
Table 1: Antibodies and dilutions used for immunoblotting. 
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3.3.5 Two-dimensional gel electrophoresis 
Cells were lysed and protein quantified as described above. Four times the volume of ice-cold 
acetone (Fisher Scientific, Pittsburgh, PA, USA) was added to 50-75 µg of protein. Lysates were 
vortexed and incubated at -20°C for one hour. Precipitated proteins were then collected by 
centrifugation at 15,000 x g for 15 minutes. The resulting supernatant was decanted and pellet 
dried at room temperature for 30 minutes. The pellet was then resolubilized in 250 µLs of 
rehydration buffer containing: 7 M urea (Invitrogen, Carlsbad, CA, USA), 2 M thiourea 
(Invitrogen, Carlsbad, CA, USA), 2% CHAPS (Sigma-Aldrich Corp., St. Louis, MO, USA), 50 
mM DTT (Sigma-Aldrich Corp., St. Louis, MO, USA), and 5 µL of pH 3-11 ampholytes (GE 
Healthcare, Piscataway, NJ, USA).  
The BioRad Protean IEF cell (Bio-Rad, Hercules, CA, USA) was used to perform active 
in-gel rehydration of IPG strips (pH 3-11) (GE Healthcare, Piscataway, NJ, USA) and isoelectric 
focusing. Following focusing, proteins were reduced by incubating IPG strips in equilibration 
buffer (375 mM Tris-HCl, pH 8.8, 6 M urea, 2% SDS) with 0.13 M DTT for 10 minutes, and 
alkylated in equilibration buffer plus 35 mg/mL iodoacetamide (Sigma-Aldrich Corp., St. Louis, 
MO, USA) for 10 minutes. Strips were then loaded into SDS-PAGE gels and resolved at 90 
volts. Proteins were transferred and immunoblotted as described above.  
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3.4 IMAGE ANALYSES 
3.4.1 Immunocytochemistry 
Media was aspirated, and cells washed once in DPBS before fixation. When staining for 
endogenous LC3, cells were fixed in methanol (Fisher Scientific, Pittsburgh, PA, USA) for five 
minutes at -20°C. In all other experiments, cells were fixed in 4% paraformaldehyde (Sigma-
Aldrich Corp., St. Louis, MO, USA) at room temperature for 15 minutes. The fixed cells were 
then washed twice with DPBS before being permeabilized in PBS containing 0.1% Triton-X 
(Fisher Scientific, Pittsburgh, PA, USA), for 30 minutes at room temperature. In some 
experiments, cells were incubated in rhodamine-phalloidin (1:5000) (Invitrogen, Carlsbad, CA, 
USA) for 15 minutes. Background staining was reduced by blocking in SuperBlock (Thermo 
Scientific, Rockford, IL, USA) for one hour at room temperature. Primary antibodies diluted in 
commercial antibody diluent at indicated concentrations (Table 2) were applied overnight at 4°C. 
Cells were then washed three times for five minutes before being incubated for one hour at room 
temperature in Alexa-488 or Alexa-546 secondary antibodies (Invitrogen, Carlsbad, CA, USA) 
diluted 1:1000. Following three more PBS washes, cells were imaged with an oil objective on an 
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3.4.2 Neurite length 
Forty-eight hours after plating on Nunc Labtek 1.0 borosilicate glass 4-well chamber slides, SH-
SY5Y cells were transfected. Seventy-two hours after transfections cells were fixed and stained. 
Neurite length was quantified by GFP fluorescence or rhodamine-phalloidin staining using 
ImageJ. 
3.4.3 Primary dendrite analysis 
Seven days after plating on Labtek 1.0 borosilicate glass 4-well chamber slides, mouse primary 
cortical neurons were transfected. Neurons were fixed and stained seven days post-transfection. 
Dendrites were manually traced in Adobe Photoshop CS5. The number of dendrites directly 
branching off the soma was then manually counted. 
 
 
Antigen Dilution Company 
FLAG 1:1,000 Sigma-Aldrich Corp., St. Louis, MO, USA 
GFP 1:5,000 Invitrogen, Carlsbad, CA, USA 
HA 1:1,000 Invitrogen, Carlsbad, CA, USA 
LC3 1:250 Novus Biologicals, Littleton, CO, USA 
MAP2 1:2,500 Millipore, Billerica, MA, USA 
MYC 1:1,000 Cell Signaling Technology, Danvers, MA, USA 
Table 2: Antibodies and dilutions used for immunocytochemistry 
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3.4.4 Sholl analysis 
Seven days after plating on Labtek 1.0 borosilicate glass 4-well chamber slides, mouse primary 
cortical neurons were transfected. Neurons were fixed and stained seven days post-transfection. 
Dendrites were manually traced in Adobe Photoshop CS5. Skeletons were then extracted and 
subjected to Sholl analysis using the ImageJ ShollAnalysis plugin [201]. Analysis parameters 
include a starting radius of 20 µm, ending radius of 100 µm, and step size of 10 µm. A schematic 
representation of the analysis is depicted in Figure 7.  
3.4.5 Dendritic spine analysis  
Seven days after plating on Labtek 1.0 borosilicate glass 4-well chamber slides, mouse primary 
cortical neurons were transfected with IRES-GFP or PINK1-IRES-GFP. Neurons were fixed and 
Figure 7: Neuronal morphology analysis. 
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stained seven days post-transfection. Neurons were imaged on a Nikon A1 Spectral confocal 
microscope. The number and morphology of dendritic spines in a 50 µm segment of secondary 
dendrite were manually analyzed and quantified. Filopodia were defined as long, thin protrusions 
without a discernible spine head. All other protrusions were considered spines.  
3.4.6 Autophagosome number  
SH-SY5Y cells were fixed 72 hours after transfection, and stained for HA-LC3 or endogenous 
LC3. LC3 positive puncta per cell with a fluorescent intensity equal or greater to 1.5 times the 
standard deviation of the cytosolic mean intensity were quantified 
3.5 STATISTICAL ANALYSES 
Statistical analyses were performed using GraphPad Prism 6. The unpaired Student’s t-test was 
used to compare means between two groups. One-way ANOVA was employed when necessary 
to measure the effect of one independent variable between more than two groups, and two-way 
ANOVA was utilized to compare differences between groups with two or more independent 
variables. Bonferroni’s correction for multiple comparisons was used when more than two 
groups were being analyzed. P-values of ≤ 0.05 were considered statistically significant.   
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4.0  RESULTS 
4.1 PINK1 PROMOTES NEURONAL DIFFERENTIATION 
To date, studies of PINK1 function have largely focused on its role in maintaining mitochondrial 
homeostasis, despite a dual localization within cytosol. Interestingly, mitochondrial localization 
is not required for PINK1 to protect against neuronal cell death induced by complex I inhibition 
[7] and oxidative stress [117] suggesting that the cytosolic activities of PINK1 are important for 
neuronal health. To investigate the effect of PINK1 activity on neuronal morphology, WT- and a 
kinase-deficient mutant (K219M)-PINK1 were transfected into undifferentiated SH-SY5Y cells. 
Corroborating an earlier report [110], WT- but not K219M-PINK1-GFP, promotes neurite 
extension (Fig. 8A-B). Dendritic arbors are highly complex and dynamic structures that receive 
input from other neurons. Stabilization and maintenance of appropriate connections between 
neurons is essential for their highly specialized functions.  Simplification of dendritic arbors has 
been observed in a wide-variety of neurological disorders [202] including PD [36, 203]. 
Consistent with a pro-differentiation function, PINK1 overexpression promotes dendrite 
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Figure 8: PINK1 promotes neurite extension and dendritic complexity. (A) Representative 
images of SH-SY5Y cells expressing GFP, WT-, or kinase-deficient (K219M)-PINK1-GFP. 
Scale bar=10 µm. (B) Quantification of neurite length in SH-SY5Y cells (Mean±SEM; 30-44 
cells/group compiled from two independent experiments; *P-value<0.05 vs. GFP). (C) 
Representative images of mouse cortical neurons expressing IRES-GFP or PINK1-IRES-
GFP. Scale bar=50 µm. (D) Sholl analyses of cortical neuron dendritic arbors (Mean±SEM; 
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4.2 PINK1 INTERACTS WITH VCP 
4.2.1 Mass spectrometric identification of PINK1-VCP interaction 
An unbiased proteomic approach was utilized to identify potential proteins with which PINK1 
interacts to exert these effects on neuronal differentiation. GFP immunoprecipitations (IPs) were 
performed on lysates from HEK293 cells overexpressing GFP or PINK1-GFP, and IP products 
were subjected for mass spectrometric analysis. Unsurprisingly, PINK1 was identified as the 
most abundant protein in the PINK1-GFP IP sample with a sequence coverage of 63.6215% and 
Log2 ratio of spectral counts (PINK1-GFP:GFP) of 9.699 (Table 3, Fig. 9A). VCP (sequence 
coverage 24.194%, Fig. 9B) was among the most enriched proteins co-IPed by PINK1-GFP, 
with a Log2 ratio comparable to that of two chaperones, CDC37 and HSP90A, known to bind 
PINK1 and prevents its degradation (Table 3, [69]). We elected to pursue VCP as a candidate 
PINK1-interacting protein because, like PINK1, VCP regulates neuronal morphology and 













PINK1 9.699 63.621 
CDC37 6.570 42.328 
VCP 6.476 24.194 
HSP90A 2.344 50.410 
Table 3: PINK1 interacting proteins identified by mass spectrometry. 
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4.2.2 Immunoblot validation of PINK1-VCP interaction 
To confirm that PINK1 interacts with VCP, GFP IP followed by immunoblotting was performed 
on HEK293 cell lysates (Fig. 10B). Further, in reciprocal IPs performed on HEK293 lysates, 
VCP-GFP pulled down exogenous FL- and ΔN-PINK1-3xFLAG (Fig. 10C). To determine 
whether PINK1 interacts with VCP in neuronal cells, endogenous VCP was IPed in vector (M14) 
and PINK1-3xFLAG overexpressing (#24) SH-SY5Y stable cell lines. Similar to the results in 
HEK293 cells, endogenous VCP pulled down PINK1 in a PINK1-3xFLAG overexpressing cell 
line. These immunoblot analyses suggest that the PINK1-VCP interaction is tag-independent and 
the proteins associate both in neuronal and non-neuronal cells. 
Figure 9: Sequence coverage of PINK1 and VCP in PINK1-GFP IP products. (A) PINK1 
peptides identified by mass spectrometry (sequence coverage=63.6215) in PINK1-GFP IP 
products highlighted in green (B) VCP peptides detected in PINK1-GFP IP products 
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Figure 10: Immunoblot validation of PINK1-VCP interaction. (A) Immunoblot representation 
of PINK1-3xFLAG pulled down by endogenous VCP immunoprecipitated from vector (M14) 
and PINK1-3xFLAG overexpressing (#24) SH-SY5Y cell lines. Immunoblot is representative 
of three independent experiments. (B) Immunoblot of GFP immunoprecipitation products of 
HEK-293 cells expressing GFP or WT-PINK1-GFP. Immunoblot is representative of 5 
independent experiments. (C) Immunoblot of GFP immunoprecipitation products from HEK-
293 cells co-expressing GFP or VCP-GFP and ΔN-PINK1-FLAG or WT-PINK1-FLAG. 
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4.2.3 Mitochondrial localization is not required for PINK1-VCP binding 
As described in the introduction, mitochondrial localization of PINK1 is required for many of its 
regulatory effects on mitochondrial homeostasis. Additionally, VCP associates with 
mitochondria under certain conditions [145, 147] and promotes mitochondrial homeostasis [142, 
143]. To determine whether mitochondrial localization is required for its interaction with VCP, 
PINK1 constructs lacking a mitochondrial targeting sequence (ΔN-PINK1-GFP) or targeted to 
the outer mitochondrial membrane (OMM-PINK1-GFP) were employed. HEK293 cells 
expressing these lysates were subjected to GFP IPs followed by immunoblotting. Despite 
approximately equivalent expression in the input, ΔN-PINK1-GFP pulled down approximately 
four times more VCP than OMM-PINK1-GFP (Fig 11A-B). To determine whether 
mitochondrial injury promotes the association of VCP with PINK1 targeted to the outer 
mitochondrial membrane, HEK293 cells were treated with 10µM of the protonophore FCCP for 
two hours. Dissipation of mitochondrial membrane potential did not increase the amount of VCP 
pulled down by OMM-PINK1-GFP (Fig. 11C). These data demonstrate that mitochondrial 
localization is not required for PINK1-VCP binding, suggesting that the cytosolic pool of PINK1 













Figure 11: Mitochondrial localization is not required for PINK1-VCP interaction. (A) 
Representative immunoblot of GFP IP products from HEK293 cells expressing GFP, ΔN-
PINK1-GFP, OMM-GFP, and OMM-PINK1-GFP. (B) Densitometric analysis of co-IPed 
VCP normalized to density of GFP. Data are expressed as mean±SEM from three independent 
experiments (*P-value<0.0001). (C) Representative immunoblot of GFP IP products from 
HEK293 cells expressing GFP, ΔN-PINK1-GFP, OMM-GFP, and OMM-PINK1-GFP treated 
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4.2.4 PINK1 does not regulate post-translational modification of VCP 
PINK1 kinase activity is required for its ability to protect against cell death [7, 204] and promote 
neuronal differentiation (Fig 8A-B; [110]). To determine whether VCP is a direct or indirect 
target of PINK1 kinase activity, lysates from PINK1 overexpressing cells were subjected to 
analysis by 2-D SDS-PAGE. VCP isoelectric focusing was not significantly altered in non-
neuronal (HEK293) (Fig. 12A) or neuronal (SH-SY5Y) (Fig. 12B) cells overexpressing PINK1. 
This result suggests that VCP is not a PINK1 substrate. 
Figure 12: PINK1 overexpression does not alter isoelectric focusing of VCP. (A) 2-D 
immunoblots of vector (M14) and PINK1-3xFLAG overexpressing (#24) SH-SY5Y cell lines 
probed for VCP. Immunoblots are representative of three independent experiments. (B) 2-D 
Immunoblots of HEK293 cells expressing GFP or WT-PINK1-GFP probed for VCP. 
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4.3 VCP ACTS DOWNSTREAM OF PINK1 TO PROMOTE NEURITE EXTENSION 
AND DENDRITIC COMPLEXITY 
4.3.1 VCP overexpression protects against PINK1 KD induced neurite retraction 
To determine whether VCP and PINK1 regulate neuronal morphogenesis through a shared 
mechanism, the ability of VCP overexpression to protect against PINK1 knockdown was 
assessed. Transient knockdown of PINK1 caused an approximately 10 µm reduction of neurite 
length in undifferentiated SH-SY5Y cells. This neurite shortening is reversed by VCP 
overexpression (Fig. 13A-B). Though the exact mechanism is elusive, PINK1 and PKA signaling 
converge to regulate mitochondrial calcium extrusion and promote neurite extension through 
convergent pathways [87, 110]. To determine whether inactivation of cAMP signaling pathways 
was required for the rescue by VCP overexpression, neurite length was measured in PINK1 
deficient SH-SY5Y cells treated with the 250 nM of the PKA inhibitor H89 for 14 hours.  PKA 
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Figure 13: VCP overexpression prevents neurite shortening induced by PINK1 knockdown. 
(A) Representative images of SH-SY5Y cells transfected with scrambled or PINK1 siRNA 
and GFP or VCP-GFP. Scale bars=10µm. (B) Neurite length quantification of SH-SY5Y cells 
in (A) (Mean±SEM; 196-222 cells/group compiled from 4 independent experiments, *P-
value<0.0001 vs. siCTRL + GFP). (C) Neurite length of SH-SY5Y cells transfected with 
scrambled or PINK1 siRNA and GFP or VCP-GFP and treated with DMSO or 250 nM H89 
for 14 hours (Mean±SEM; 87-134 cells/group compiled from two independent experiments, 
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4.3.2 PINK1 requires VCP expression to promote dendrite complexity 
The effect of VCP knockdown on the ability of PINK1 to promote dendritic complexity was also 
examined. Expression of a microRNA construct that targets mouse VCP reduced expression of 
exogenous mouse VCP-MYC expressed in HEK293 cells (Fig. 14A) as assessed by immunoblot, 
and endogenous VCP in mouse primary cortical neurons as assessed by immunofluorescence 
(Fig. 14B). Expression of miRVCP-GFP does not seem to cause significant cell death in 
transfected neurons by qualitative assessment, or have a basal effect on dendritic arbors in mouse 
cortical neurons, but inhibits the increased dendritic arborization induced by overexpression of 
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Figure 14: PINK1 requires VCP to promote dendritic complexity. Validation of VCP 
knockdown in HEK293 cells (A) co-expressing miRCTRL-GFP or miRVCP-GFP and vector 
or FL-VCP (mouse)-MYC and mouse primary cortical neurons expressing miRCTRL-GFP or 
miRVCP-GFP (B) Scale bars=25µm. (C) Representative images and dendrite tracings (inset) 
of cortical mouse neurons transfected with miRCTRL-GFP or miRVCP-GFP and vector or 
PINK1-FLAG. Scale bars=50 µm. (D) Quantification of primary dendrites and (E) Sholl 
analyses of dendritic arbors performed on neurons from (C) (mean±SEM; 10-13 neurons/group 
compiled from three independent experiments; *P-value<0.001 vs. miRCTRL-GFP + vector, 
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4.3.3 PINK1 interacts with the D1 domain of VCP 
To identify the region of VCP that binds to PINK1, a series of MYC-tagged VCP domain 
constructs (Fig. 15A) were expressed in HEK293 cells in tandem with PINK1-3xFLAG. The N-
terminal co-factor binding domain and D2 ATPase domain were insufficient for VCP-PINK1 
binding, but all constructs containing the D1 domain were co-IPed by PINK1-3xFLAG (Fig. 
15B). Interestingly, far less monomeric D1 is pulled down by PINK1 than its dimer or the 
construct containing both the N and D1 domains. This finding emphasizes the importance of the 
quaternary structure of VCP for its association with PINK1. 
Figure 15: Interaction of VCP with PINK1 requires the D1 domain. (A) Schematic 
representation of VCP truncation constructs used and the 3-D structure of VCP. (B) 
Immunoblot of FLAG immunoprecipitation products from HEK293 cells expressing indicated 
MYC-tagged VCP domain constructs and PINK1-3xFLAG. Immunoblot is representative of 
four independent experiments. 
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Figure 16: Overexpression of PINK1-binding domain of VCP blocks the effect of PINK1 
overexpression on neurites. (A) Representative images of SH-SY5Y cells co-expressing IRES-
GFP or PINK1-IRES-GFP and indicated MYC-tagged VCP domain constructs. Scale 
bar=10µm. (B) Neurite length quantification of cells in (A). Data are represented as 
mean±SEM (58-72 cells/group compiled from three independent experiments). (C) 
Representative images of cortical neurons co-transfected with IRES-GFP or PINK1-IRES-GFP 
and indicated MYC-tagged domains of VCP. Scale bar=50 µm. (D) Sholl analyses of dendritic 
arbors from neurons in (C). Green lines represent neurons co-expressing IRES-GFP and pink 
lines represent neurons co-expressing PINK1-IRES-GFP (Mean±SEM; 10-14 neurons/group 
from three independent experiments; *P-value<0.0001 vs. IRES-GFP+FL-VCP-MYC; #P-
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The importance of VCP function in PINK1 induced neurite extension and dendrite 
arborization was further confirmed by expressing these domains in neuronal cells. 
Overexpression of PINK1-binding domains (D1 and ND1) inhibited PINK1-induced neurite 
outgrowth in SH-SY5Y cells (Fig. 16A-B). Additionally, PINK1 does not promote dendrite 
complexity in cortical neurons when co-expressed with the D1 domain of VCP (Fig. 16C-D). 
While expression of the D1-domain did not have a basal effect on dendrite morphology, its co-
expression with PINK1 resulted in further simplification of the dendritic arbor. Taken together, 
these data identify VCP as a necessary downstream mediator of PINK1 induced neurite 
outgrowth.  
4.3.4 PINK1 requires NF1 to promote neurite outgrowth and dendrite complexity 
VCP interacts with NF1 to promote dendritic spinogenesis [152] and NF1 induces dendritic 
filopodia formation and neurite outgrowth through PKA-dependent mechanisms [170]. To 
determine whether NF1 was involved in PINK1-induced neurite outgrowth, VCP binding to NF1 
was assessed in PINK1 overexpressing neuronal cells. Comparable amounts of VCP were co-
IPed by endogenous NF1 IP in vector (M14) and PINK1-3xFLAG overexpressing (#24) SH-
SY5Y cell lines as assessed by immunoblot (Fig. 17A). The D1 domain of VCP mediates its 
association with both NF1 [152] and PINK1 (Fig. 15B). Despite this, PINK1 overexpression 
does not outcompete NF1 for VCP binding, suggesting that PINK1, VCP, and NF1 may form a 
functional complex. 
To explore this possibility, neurite length and dendrite complexity were analyzed in NF1 
deficient neuronal cells. As with VCP knockdown (Fig. 14B,D), NF1 deficiency alone did not 
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significantly reduce neurite length in SH-SY5Y cells (Fig. 17C,E), but was sufficient to prevent 
PINK1 induced neurite outgrowth and dendritic arborization (Fig 17C-F). Interestingly, PINK1 
overexpression in NF1 deficient neurons caused simplification of the dendritic arbor compared to 
control neurons (siCTRL+IRES-GFP). This result mirrors the effect of simultaneous expression 
of PINK1 and the D1 domain of VCP (Fig. 16C-D).  Cumulatively, these data indicate that 







  59 
 
Figure 17: PINK1 requires NF1 expression to promote dendritic complexity. (A) Immunoblot of 
endogenous NF1 immunoprecipitation products from stable vector (M14) and PINK1-3xFLAG 
(#24) SH-SY5Y cell lines. Immunoblot is representative of two independent experiments. (B) 
Immunoblot validation of NF1 knockdown in HEK293 cells. Immunoblot represents one 
experiment. (C) Representative images of SH-SY5Y cells co-transfected with scrambled or NF1 
shRNA and IRES-GFP or PINK1-IRES-GFP. Scale bar=10 µm. (E) Neurite length 
quantification of cells from (B). Data are represented as mean±SEM (86-98 cells/group compiled 
from three independent experiments; *P-value<0.001 vs. IRES-GFP+shCTRL). (D) 
Representative images of primary cortical neurons co-transfected with scrambled or NF1 siRNA 
and IRES-GFP or PINK1-IRES-GFP. Scale bar=50 µm. (F) Sholl analyses of dendritic arbors 
from neurons in (D). Data are represented as mean±SEM (9-12 neurons/group; *P-value<0.01 
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4.3.5 VCP binding is impaired in two PD-associated PINK1 mutants 
A panel of PD-associated PINK1-GFP mutants generated by site-directed mutagenesis of the 
parental plasmid was used to evaluate the effect of these mutations on VCP-binding (Fig. 18A). 
HEK293 cells were transfected with these constructs, and resulting lysates were subjected to 
GFP immunoprecipitation. As assessed by immunoblot, G309D- and G409V-PINK1-GFP pulled 
down significantly less VCP than WT-PINK1-GFP (Fig. 18B-C). VCP pull-down was 
normalized to the band that migrates at the predicted molecular weight of full-length PINK1-
GFP. To determine whether the ability of these PD-associated PINK1 constructs to promote 
neurite extension was impaired by deficient VCP binding, neurite length was measured in SH-
SY5Y cells expressing G309D- and G409V-PINK1-GFP. These two PD-associated PINK1 
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Figure 18: G309D- and G409V-PINK1-GFP co-immunoprecipitate less VCP and fail to 
promote neurite extension. (A) Schematic representation of PINK1 domains including PD-
associated mutants used. (B) Immunoblot of GFP immunoprecipitation products from 
HEK293 cells transfected with GFP, WT-, or PD-associated PINK1-GFP mutants. (C) 
Densitometric analysis of VCP co-immunoprecipitated with PINK1-GFP normalized to GFP 
density. Data are represented as mean±SEM from four independent experiments (*P-
value<0.05 vs. WT-PINK1-GFP). (D) Representative images of SH-SY5Y cells transfected 
with GFP, WT-, G309D-, or G409V-PINK1-GFP and stained with rhodamine-phalloidin. 
Scale bar=10 µm. (E) Quantification of neurite lengths from cells in (D). Data are represented 
as mean±SEM (78-100 cells/group compiled from four independent experiments; *P-
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4.4 PINK1 INTERACTS WITH CRMP2 
NF1 associates with CRMP2 to regulate neurite length [172]. Interestingly, a quantitative 
proteomics study recently discovered reduced expression of several proteins involved in 
neuronal morphogenesis and synaptic plasticity, including CRMP2, in the brains of PINK1 KO 
mice [205]. To determine whether CRMP2 is a component of the PINK1-VCP signaling hub, 
GFP IP products from HEK293 cells expressing PINK1-GFP were probed for CRMP2. CRMP2 
was co-immunoprecipitated by PINK1 (Fig. 19A). Additionally, VCP-GFP co-IPs CRMP2, but 
the amount pulled down was dramatically increased upon co-expression with PINK1-3xFLAG 
(Fig. 19B). Further, co-expression of MYC-VCP had little effect on the amount of CRMP2 
pulled down by PINK1-GFP (Fig. 19C), suggesting that this association is predominantly 
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Figure 19: PINK1 interacts with CRMP2. (A) Representative immunoblot of GFP 
immunoprecipitation products from HEK293 cells expressing GFP or PINK1-GFP. 
Immunoblot represents three independent experiments. (B) Immunoblot of GFP 
immunoprecipitation products from HEK293 cells co-transfected with GFP or VCP-GFP and 
vector or PINK1-FLAG. Immunoblot represents one experiment. (C) Immunoblot of GFP 
products from HEK293 cells co-transfected with GFP or PINK1-GFP and vector or VCP-
MYC. Immunoblot represents one experiment. 
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4.4.1 PINK1 regulates CRMP2 phosphorylation 
NF1 regulates phosphorylation of CRMP2 [172]. To determine whether PINK1 also contributes 
to this regulation in neuronal cells, whole cell lysates from vector (M14) and PINK1-3xFLAG 
overexpressing (#24) SH-SY5Y cell lines were subjected to analysis by 2-D SDS-PAGE and 
probed for CRMP2. The intensity of multiple spots was dramatically increased in PINK1 
overexpressing cell lines (Fig. 20A). These shifts in intensity are consistent with alterations in 
CRMP2 phosphorylation status. To further examine this possibility, levels of CRMP2 
phosphorylated at Ser522, a phosphorylation site known to promote appropriate dendritic field 
organization [196] and dendritic spine development [195] were examined in PINK1 
overexpressing SH-SY5Y cells. Phosphorylation of CRMP2 at Ser522 was increased by 
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The effect of PINK1 knockout on CRMP2 expression and phosphorylation were also 
examined. Lysates from the ventral midbrain of 6-month-old wild type and PINK1 KO mice 
were subjected to 2-D SDS-PAGE and probed for CRMP2. There was a striking shift of CRMP2 
spot intensity in PINK1 KO mice (Fig. 21A), consistent with alterations in CRMP2 
phosphorylation species. To confirm this finding, phospho-CRMP2 (Ser522) levels were assayed 
in the ventral midbrain of 6-month-old (Fig. 21B-C) and 12-month-old (Fig. 21D-E) wild type 
and PINK1 KO mice. Phosphorylation of CRMP2 was reduced by ~20% in the ventral midbrain 
of these animals. Taken together, these data identify PINK1 as regulator of CRMP2 
phosphorylation in both in vitro and in vivo model systems.  
Figure 20: PINK1 overexpression promotes phosphorylation of CRMP2 at Ser522. (A) 2-D 
immunoblots of vector (M14) and PINK1-3xFLAG (#24) overexpressing SH-SY5Y cells 
probed for CRMP2. Immunoblot represents three independent experiments. (B) Representative 
immunoblot of M14 and #24 lysates probed for pCRMP2 (Ser522) and total CRMP2. (C) 
Densitometric analysis of pCRMP2 normalized to total CRMP2 in M14 and #24 cells. Data are 
represented as mean±SEM of four independent experiments (*P-value≤0.01 vs. M14) 
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Figure 21: Phosphorylation of CRMP2 at Ser522 is reduced in PINK1 KO mice. (A) 2-D 
immunoblots of ventral midbrain lysates from six-month-old WT and PINK1 KO probed for 
CRMP2. Immunoblots are representative of three animals from each cohort. (B) 
Representative immunoblot of ventral midbrain lysates from six-month-old WT and PINK1 
KO mice probed for pCRMP2 (Ser522) and total CRMP2. (C) Densitometric analysis of 
pCRMP2 (Ser522) levels normalized to total CRMP2. Data are represented as mean±SEM of 
five animals for each cohort (*P-value=0.0279 vs. WT). (D) Representative immunoblot of 
ventral midbrain lysates from 12-month-old WT and PINK1 KO mice probed for pCRMP2 
(Ser522) to total CRMP2. (D) Densitometric analysis of pCRMP2 (Ser522) levels normalized 
to total CRMP2. Data are represented as mean±SEM of five animals from each cohort (*P-
value=0.0342 vs. WT) 
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4.4.2 PINK1 does not affect CRMP2-Tubulin binding 
Binding tubulin at the plus end to stabilize microtubules, is the canonical function of CRMP2 
known to regulate neuronal morphology [174]. Hyperphosphorylation of CRMP2 promotes its 
dissociation from tubulin heterodimers, resulting in neurite retraction. To determine whether 
PINK1 affect the ability of CRMP2 to bind tubulin, endogenous CRMP2 was IPed from vector 
(M14) and PINK1 overexpressing (#24) SH-SY5Y cell lines. There was not an observable 
difference in the amount of tubulin pulled down by CRMP2 between these cell lines (Fig. 22). 
This finding suggests the mechanism by which PINK1-VCP promotes neuronal differentiation 
does not alter CRMP2-tubulin binding.  
Figure 22: PINK1 does not alter CRMP2 binding to tubulin. Immunoblot of endogenous 
CRMP2 immunoprecipitation products from vector (M14) and PINK1-3xFLAG 
overexpressing SH-SY5Y cell lines probed for β-tubulin III and CRMP2. Data represents 
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4.5 PINK1 REGULATES SYNAPSES 
VCP [155], NF1 [152, 170], and phosphorylation of CRMP2 at Ser522 [195] all contribute to the 
regulation of dendritic spinogenesis. To determine if PINK1 also contributes to formation and 
maintenance of synapses, ventral midbrain lysates from PINK1 KO and wild type mice were 
analyzed by immunoblot. Expression of pre-synaptic (VGLUT1, SYN1) and post-synaptic 
(PSD95) markers was unaltered in PINK1 KO mice at three months (Fig. 23A,D-F).  Further, 
loss of PINK1 did not affect protein levels of VCP or NF1 (Fig. 22A-C), and there was no 
correlation between NF1 expression and synaptic marker expression (Fig. 23G-I). By six 
months, expression of all probed synaptic markers was significantly lower in PINK1 KO mice 
(Fig. 24A, D-F) concomitant with a reduction in NF1 expression (Fig. 24A, C). Interestingly, 
NF1 expression is strongly correlated with expression of all probed synaptic markers at this age 
(Fig. 24A, G-I). These data suggest that loss of PINK1 function causes an age-dependent loss of 
synapses in the ventral midbrain of mice.  
To more directly assess the effect of PINK1 expression on dendritic spinogenesis, spine 
density and morphology were analyzed in mouse cortical neurons were transfected with PINK1-
IRES-GFP.  Seven days after transfection (DIV 14), there was not a significant difference in total 
number of protrusions/50 µm (Fig. 25A-B). However, at this time point, PINK1 overexpression 
caused a reduction in the number of dendritic filopodia with a concurrent increase in the number 
of spines (Fig 25A-B). Cumulatively, these results suggest that PINK1 contributes to the 
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Figure 23: Expression of synaptic markers is unaltered at 3 months in PINK1 KO mice. (A) 
Representative immunoblot of ventral midbrain lysates from 3-month-old WT and PINK1 KO 
mice. Densitometric analysis of VCP (B), NF1 (C), VGLUT1 (D), PSD95 (E), and 
synaptophysin (SYN) (F) normalized to β-actin. Data are represented as mean±SEM of five 
mice from each cohort. Regression analyses of NF1 expression vs. VGLUT1 (G), PSD95 (H) 
and SYN (I) expression. NF1 expression did not correlate with expression of any of the 
synaptic markers at this time point with R2  values of 0.1474, P-value=0.2734 (G), 0.1664, P-
value=0.2419 (H), and 0.2778, P-value=0.1175 (I).  
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Figure 24: Expression of synaptic markers is decreased at 6 months in PINK1 KO mice. (A) 
Representative immunoblot of ventral midbrain lysates from 6-month-old WT and PINK1 KO 
mice. Densitometric analysis of VCP (B), NF1 (C), VGLUT1 (D), PSD95 (E), and 
synaptophysin (SYN) (F) normalized to β-actin. Data are represented as mean±SEM of five 
mice from each cohort (*P-value<0.05 vs. WT). Regression analyses of NF1 expression vs. 
VGLUT1 (G), PSD95 (H) and SYN (I) expression. NF1 expression was positively correlated 
with expression of all of the synaptic markers at this time point with R2  values of 0.5305, P-
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4.6 PINK1 AND VCP CO-REGULATE AUTOPHAGY 
4.6.1 PINK1 expression modulates sensitivity to autophagy induced by chemical 
inhibition of VCP 
PINK1 knockdown promotes autophagosome accumulation [117, 118]. Similarly, VCP 
inactivation by chemical inhibition [206] or expression of ATPase deficient mutants [133, 207] 
results in the accrual of autophagosomes. Overexpression of PINK1 also protects against 
autophagic stress in cells treated with 6-OHDA [198]. In order to determine whether PINK1 
modulates autophagy induced by VCP-inhibition, LC3 lipidation was monitored in PINK1 
overexpressing cells treated with the VCP inhibitor DBeQ.  LC3-II levels were significantly 
reduced in both non-neuronal HEK293 (Fig. 26A-B), and neuronal SH-SY5Y (Fig. 26C-D) cells 
Figure 25: PINK1 promotes dendritic spinogenesis. (A) Representative images of dendritic 
spines in mouse cortical neurons expressing IRES-GFP or PINK1-IRES-GFP. (B) Quantification 
of filopodia and spine density in neurons from (A). Data are represented as mean±SEM (n=8-9 
neurons/group collected from three independent experiments, *P-value<0.05).  
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overexpressing PINK1. Additionally, transient knockdown of PINK1 sensitized SH-SY5Y cells 
to autophagosome accumulation following treatment with DBeQ (Fig. 26E-F).  
 
Figure 26: PINK1 modulates sensitivity to VCP inhibition. (A) Representative immunoblot of 
lysates from HEK293 cells transfected with GFP or PINK1-GFP and treated with indicated doses 
of the VCP inhibitor DBeQ for four hours. (B) Densitometric analysis of LC3-II normalized to 
GAPDH. Data are represented as mean±SEM compiled from four independent experiments (*P-
value<0.0001 vs. GFP+20µM DBeQ).  (C) Representative immunoblot of lysates from vector 
(M14) and PINK1-3xFLAG (#24) SH-SY5Y cell lines treated with indicated doses of DBeQ for 
four hours. (C) Densitometric analysis of LC3-II normalized to GAPDH. Data are represented as 
mean±SEM compiled from three independent experiments (*P-value<0.001 vs. M14+15 µM 
DBeQ).  (D) Representative immunoblot of lysates from SH-SY5Y cells transfected with 
scrambled or PINK1 siRNA and treated with indicated doses of DBeQ for four hours. (E) 
Densitometric analysis of LC3-II normalized to GAPDH. Data are represented as mean±SEM 
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4.6.2 VCP protects against autophagosome accumulation induced by PINK1 knockdown 
To determine whether VCP overexpression was sufficient to prevent autophagosome 
accumulation in PINK1 deficient cells, LC3 puncta were quantified in SH-SY5Y cells. Transient 
knockdown of PINK1 caused accumulation of autophagosomes (Fig. 26A-B), consistent with an 
earlier observation in stable PINK1 knockdown cell lines [117]. Accumulation of LC3 puncta 
was reversed by co-transfection with VCP-GFP (Fig. 27A-B), suggesting that VCP is unlikely to 
act upstream of PINK1 autophagy regulation as well as neuronal morphogenesis. 
Figure 27: VCP overexpression protects against autophagy induced by PINK1 knockdown. (A) 
Representative images of SH-SY5Y cells co-transfected with scrambled or PINK1 siRNA and 
GFP or VCP-GFP and immunostained for endogenous LC3. Scale bar=10 µm. (B) 
Quantification of autophagosomes in SH-SY5Y cells co-transfected with scrambled or PINK1 
siRNA and GFP or VCP-GFP (Mean±SEM; 43-44 cells/group compiled from three independent 
experiments; *P-value<0.0001 vs. siCTRL+GFP). 
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4.6.3 Role of autophagy in PINK1-induced neurite extension 
Autophagy induced neurite retraction has been observed in genetic and toxin models of PD [199, 
208]. To examine whether autophagy suppression contributes to PINK1 induced neurite 
outgrowth, the essential autophagy protein ATG7 was transiently knocked down in PINK1 
overexpressing cells. ATG7 knockdown did not further promote neurite extension in 
undifferentiated SH-SY5Y cells overexpressing PINK1 (Fig. 28A-B). Neurite length was 
sufficiently increased by ATG7 silencing in SH-SY5Y cells expressing GFP, to make the 
comparison with PINK1-GFP statistically insignificant.  This finding suggests that suppression 
of autophagosome accumulation contributes, but is not the sole mechanism through which 
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4.6.4 PKA phosphorylation of LC3 in PINK1 overexpressing cells 
LC3 phosphorylation by PKA at Ser12 suppresses autophagy, and protects against neurite 
shortening in genetic and toxin models of PD [199]. Given that PKA signaling is implicated in 
PINK1-VCP induced neurite outgrowth (Fig. 12C), regulation of this phosphorylation site was 
examined in PINK1 overexpressing SH-SY5Y cells. PINK1-3xFLAG overexpression (#24 cell 
Figure 28: ATG7 knockdown abrogates neurite length differences between SH-SY5Ys 
expressing GFP and PINK1–GFP. (A) Representative images of SH-SY5Y cells co-
transfected with scrambled or ATG7 siRNA and GFP or PINK1-GFP and stained with 
rhodamine-phalloidin. Scale bar=10 µm. (B) Quantification of neurite length in SH-SY5Y 
cells co-transfected with scrambled or ATG7 siRNA and GFP or PINK1-GFP (Mean±SEM; 
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line) caused an unexpected and dramatic reduction in density of the ~20 kDa phospho-LC3 
(Ser12) band (Fig 29A-B). Intriguingly, a concomitant increase in density of a high molecular 
weight (>250 kDa) pLC3-immuonreactive band was also observed in these lysates (Fig. 29A, C). 
To verify that this high molecular weight band was PKA phosphorylated- LC3, vector (M14) and 
PINK1-3xFLAG (#24) cells were treated with a PKA inhibitor (H89). Surprisingly, the 20 kDa 
pLC3 band was largely unaffected by this treatment, but there was a striking reduction in density 
of the >250 kDa band (Fig. 30).  
To examine the functional consequence of this phosphorylated species of LC3 in PINK1 
overexpressing cells, LC3 puncta number and neurite length were quantified in SH-SY5Y cells 
expressing an unphosphorylatable LC3 mutant (S12A-LC3). Consistent with earlier work [199], 
expression of this mutant doubled the number of LC3-HA puncta per cell, and caused a slight, 
but non-significant reduction of neurite length in GFP expressing cells (Fig. 29D-E). PINK1 
overexpression had no effect on S12A-LC3-HA puncta formation, suggesting that PINK1 acts 
either upstream of PKA or in a parallel pathway to regulate autophagy. This autophagy induction 
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Figure 29: LC3 phosphorylation at Ser12 in PINK1 overexpressing cells. (A) Representative 
immunoblot of vector (M14) and PINK1-3xFLAG (#24) overexpressing stable SH-SY5Y cell 
lines lysates probed for pLC3 (Ser12) and total LC3. (B) Densitometric analyses of the ~25 
kDa (B) and >250 kDa (C) bands recognized by the pLC3 antibody normalized to GAPDH. 
Data are represented as mean±SEM of four independent experiments. (D) Representative 
images of SH-SY5Y cells co-transfected with IRES-GFP or PINK1-IRES-GFP and WT- or 
S12A-LC3-HA. Scale bar=10 µm. Quantification of WT- or S12A-LC3-HA puncta (E) and 
neurite length (F) of SH-SY5Y cells from (D). Data are represented as mean±SEM (n=63-81 
cells/group; *P-value<0.05 vs. IRES-GFP+WT=LC3-HA).  
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4.6.5 PINK1 overexpression promotes accumulation of high molecular weight 
ubiquitinated proteins 
PINK1 is the first identified ubiquitin kinase [4, 100, 101]. Since phosphorylation of ubiquitin by 
mitochondrially localized PINK1 promotes mitophagy, and ΔN-PINK1 has increased kinase 
activity [60], the effect of overexpressing cytosolic PINK1 on ubiquitin was investigated. Whole 
cell lysates from HEK293 cells expressing cytosolic PINK1 and PINK1 targeted to the outer 
mitochondrial membrane were subjected to SDS-PAGE and immunoblotted for ubiquitin. 
Cytosolic, but not OMM-PINK1 caused a marked accumulation of very high molecular weight 
ubiquitinated products (Fig. 31A). This accumulation is also observed in HEK293 cells 
expressing the two PD-associated PINK1 mutants with impaired VCP binding (Fig. 31C). Levels 
of free ubiquitin are unaffected by overexpression of PINK (Fig. 31C), suggesting that this 
Figure 30: PKA inhibition prevents accumulation of high molecular weight phospho-LC3. 
Immunoblot of lysates from vector (M14) or PINK1-3xFLAG (#24) stable cell lines were treated 
with DMSO or 250 nM H89 for 14 hours. Immunoblot was probed for pLC3 and total LC3 and 




  79 
accumulation arises from suppressed degradation of ubiquitination products or promotion of 
ubiquitin conjugation. Overexpression of PINK1 alone did not cause accumulation of these 
ubiquitination products in a neuronal cell line (Fig. 31B), but buildup of these products is more 
pronounced in PINK1 overexpressing cells following treatment with the VCP inhibitor DBeQ. 
Interestingly, this accrual caused by VCP inhibition was accompanied by cleavage of PARP-1. 
This result indicates the PINK1 overexpression modulates the mechanism by which VCP 
inhibition causes toxicity. Accumulation of high molecular weight ubiquitin conjugates was 
similar between vector and PINK1-3xFLAG overexpressing cells following proteasomal 
inhibition with MG132 (Fig. 31B). This finding indicates that impaired proteasomal degradation 
is unlikely to be responsible for the buildup of these ubiquitinated proteins in PINK1 
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Figure 31: PINK1 overexpression promotes accumulation of poly-ubiquitinated proteins (A) 
Immunoblot of lysates collected from HEK293 cells transfected with GFP, ΔN-PINK1-GFP, 
OMM-GFP, or OMM-PINK1-GFP and probed for ubiquitin. Immunoblot represents three 
independent experiments. (B) Immunoblot of lysates collected from vector (M14) or PINK1-
3xFLAG overexpressing (#24) SH-SY5Y cell lines treated with DMSO, 15µM DBeQ, or 10 µM 
MG132 for four hours. Immunoblot was probed for ubiquitin and PARP-1. Immunoblot 
represents four independent experiments. (C) Immunoblot of lysates collected from HEK293 
cells transfected with GFP, WT-, G309D-, or G409V-PINK1-GFP and probed for ubiquitin. 
Immunoblot represents three independent experiments. 
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5.0  DISCUSSION 
The potential biological roles of PINK1, as with any other kinase, vary depending on its 
subcellular localization and accessibility to downstream signaling partners. A better 
understanding of the processing and regulation of PINK1 in the presence of functional 
mitochondria provide important information for spectrum of PINK1-dependent functions that 
may be disrupted by recessive PD-linked mutations. While much has been learned about the 
catabolic function of PINK1 in response to mitochondrial depolarization, another emerging body 
of data suggests that the export of processed PINK1 from healthy mitochondria may function as 
a signal of energetic competence to promote neuronal trophic responses. Very little is known 
about the signaling network through which the cytosolic pool of PINK1 relays this message.  
As an initial step to redress this discrepancy, this project aimed to identify PINK1 
interactors that contribute to its function(s) in cells with healthy mitochondria. In the course of 
this study, two cytosolic proteins (VCP, CRMP2) were found to co-IP with PINK1. Interestingly, 
both of these proteins regulate neuronal morphology in cooperation with their shared interaction 
partner NF1. This work discovered that expression of VCP and NF1 is required for PINK1 to 
promote dendritic complexity. These studies also found that PINK1 promotes the 
phosphorylation of CRMP2 at a site known to regulate dendritic field organization [196] and 
dendritic spine density [195]. Further, data shown here suggests that PINK1 and VCP cooperate 
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to regulate autophagy. These functional overlaps will be discussed in the context of known VCP, 
NF1, CRMP2, and PINK1 regulators below.   
5.1 PINK1-VCP-NF1-CRMP2 AS A SIGNALING HUB THAT REGUALTES 
NEURONAL MORPHOLOGY 
Reduced number of dendritic spines has been observed in the striatum [31-34] and substantia 
nigra [36] of post-mortem PD brains. This loss of dendritic spines is accompanied by 
simplification of the dendritic arbor [32-35]. The data presented here suggest that PINK1, VCP, 
NF1, and CRMP2 act as a signaling hub that promotes dendritic complexity and dendritic spine 
maintenance (Fig. 32).  
NF1 interacts with CRMP2 and prevent its hyper-phosphorylation in neuronal cells [172]. 
Phosphorylation of CRMP2 at Thr509 and Thr514 by GSK3-β, preceded by a priming 
phosphorylation at Ser522 by Cdk5, promotes growth cone collapse and axonal retraction [174, 
175, 182]. These axonal effects are primarily mediated through disruption of the microtubule 
stabilizing association of CRMP2 with tubulin. Interestingly, the interaction of NF1 with 
CRMP2 requires phosphorylation by Cdk5 [173]. These experiments demonstrate that while 
PINK1 promotes phosphorylation of CRMP2 at Ser522 (Fig. 19), it does not affect the ability of 
CRMP2 to pull down β-tubulin III (Fig. 21). Further, PINK1 induced neurite outgrowth and 
dendritic arborization requires expression of NF1 (Fig16B-E). One possible explanation for these 
findings is that PINK1 and NF1 collaborate to tightly regulate phosphorylation of CRMP2. In 
this scenario, PINK1 may foster phosphorylation at Ser522 and facilitate NF1-CRMP2 binding 
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to prevent its subsequent phosphorylation by GSK3-β. VCP, as a shared binding partner of 
PINK1 and NF1, may participate in this process by bringing PINK1 and NF1 into close 
proximity. CRMP2-NF1 binding and the effect of NF1 and VCP deficiency on CRMP2 
phosphorylation in PINK1 overexpressing cells will need to be assayed to test this hypothesis. 
Future experiments employing in vivo cross-linking followed by IP, or Blue native PAGE could 
be used to investigate whether PINK1, VCP, NF1, and CRMP2 form a complex.  
Previous work has established a link between PINK1 signaling and kinases and 
phosphatases known to regulate CRMP2 phosphorylation. Tau is a microtubule-associated 
protein that promotes microtubule assembly and stability. Like CRMP2, phosphorylation of tau 
by Cdk5 and GSK3-β decreases its affinity for microtubules. Overexpression of PD-associated 
G309D-PINK1 mutant, but not WT-PINK1, promotes tau hyperphosphorylation [209]. Failure to 
deactivate GSK3-β is primarily responsible for the accrual of highly phosphorylated tau in this 
context. PINK1 deficiency also inhibits serine/threonine phosphatase protein phosphatase 2A 
(PP2A) activity [118], another regulator of both tau [210, 211] and CRMP2 phosphorylation 
[175, 212-214]. Relative to other phosphorylation sites on CRMP2, Ser522 is impervious to 
PP2A-mediated dephosphorylation [212]. Further, VCP interacts with PP2A and promotes its 
phosphatase activity under certain conditions [215]. These studies suggest that PINK1-VCP may 
inhibit CRMP2 phosphorylation at Thr509 and Thr514 by modulating the activity of GSK3-β 
and PP2A.  
PKA signaling amplifies neurite outgrowth induced by PINK1 [110]. This suggests that 
PINK1 and PKA signaling pathways may converge to co-regulate neurite extension, though the 
mechanism by which PINK1 fosters PKA activation has not yet been described. This study 
determined that VCP overexpression does not prevent neurite shortening induced by PINK1 
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deficiency in the presence of a PKA inhibitor (Fig. 13C). Interestingly, reduced production of 
cAMP correlates with neurite shortening in CNS neurons of haploinsufficient NF1 mice [169]. 
Further, restoration of PKA activity prevents neurite shortening in neurons isolated from these 
mice. Therefore, it is conceivable that PINK1-VCP promotes PKA activation through 
stimulation of NF1-dependent cAMP production.  
5.2 REGULATION OF SYNAPSES BY PINK1 
Altered morphology and reduced number of dendritic spines from the substantia nigra [36] and 
striatum [216] in PD patients was reported over two decades ago. Synaptic pathologies have 
since been reported in multiple animal models of PD [217-219], though the mechanism 
underlying these defects remains poorly understood. This work has demonstrated that loss of 
PINK1 expression causes an age-dependent reduction in synaptic marker expression in the 
ventral midbrain of PINK1 KO mice (Fig. 22-23). Additionally, overexpression of PINK1 
promotes maturation of dendritic spines (Fig. 24). These observations suggest that PINK1 
regulates synapse maturation and/or preservation. This is consistent with the previously reported 
finding that loss of PINK1 expression results defects in long-term potentiation (LTP) [113].  
As described in the introduction, loss of dendritic spines from striatal neurons is a well-
established pathological feature of PD [31, 35, 216]. This striatal dendritic spine loss positively 
correlates with the reduction in number of dopaminergic projections from the SNc [35], but 
findings in animal models of PD suggest that glutamatergic inputs from the cortex also 
contribute to this pathology [220, 221]. In this project, we did not observe a significant decrease 
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in synaptic marker expression in the striatum of PINK1 KO mice at 3, 6, or 12 months (Data not 
shown). One potential explanation for this finding is that dopamine depletion from the striatum is 
not severe enough at these ages to destabilize dendritic spines. In fact, basal levels of striatal 
dopamine are unaltered in young PINK1 KO mice [112, 113], lending support to this hypothesis. 
Additionally, it is possible that alterations in both nigral and cortical input are necessary to 
induce loss of dendritic spines in the striatum, and the PINK1 KO mice used in these studies do 
not recapitulate this dysfunction at the ages evaluated in this study (or ever).    
During the course of this work, two proteins known to regulate dendritic spine density 
were identified as PINK1 interactors (Table 3, Fig. 9-10, 18). VCP physically associates with 
NF1 to promote spinogenesis [152]. Interestingly, the expression of synaptic markers was highly 
correlated with expression of NF1 in the ventral midbrain of six-month-old mice (Fig. 23G-I). 
NF1 regulates dendritic filopodia formation through a PKA-dependent mechanism [170]. 
Further, PKA potentiates calcium influx through NMDAR, a crucial regulator of LTP 
potentiation [222]. CRMP2, the other PINK1 interacting protein identified in this study (Fig. 18), 
interacts with a subunit of the NMDAR (NR2B) [223]. Dissociation of the interaction between 
CRMP2 and NR2B reduces NR2B surface expression and NMDAR current. NR2B function is 
essential for normal synaptogenesis and spine maturation [224]. Therefore, if loss of PINK1 
disrupts the interaction between CRMP2 and NR2B, deficient NMDAR activation may impair 
synaptic maintenance in PINK1 KO mice. CRMP2 also associates with a N-type voltage gated 
calcium channel CaV2.2 [191]. Phosphorylation of CRMP2 at Ser522 enhances this interaction 
[194], resulting in increased calcium entry through the channel [194, 225]. This study found that 
PINK1 regulates phosphorylation of CRMP2 at Ser522 (Fig. 19-20). Calcium entry through 
CaV2.2 at the axon terminal promotes neurotransmitter release [193]. It is conceivable that 
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diminished calcium entry through this channel, due to impaired binding with CRMP2, may 
underlie the evoked catecholamine release deficit in PINK1 KO and +/- mice [113, 114].  
Further, somatodendritic localization of these channels coincides with maturation of dendritic 
spines [226]. Study of the role of CRMP2 binding partners in the PINK1 pathway described here 
is an exciting new direction for this project that will be further discussed in section 6.1. 
Although the mitochondrial functions of PINK1 were not investigated here, another 
possible interpretation of this data is that mitochondrial dyshomeostasis underlies the synaptic 
pathology in PINK1 KO mice. Synaptic transmission is the largest consumer of ATP in the brain 
[227], and neurons are heavily reliant on mitochondrial respiration to produce energy. Loss of 
PINK1 impairs mitochondrial respiration in the cortex of aged mice [228]. The resulting 
depletion in ATP may limit the ability of PINK1 KO neurons to support the high energetic 
demands of the synapse. In addition to energy production, mitochondria also are crucial 
regulators of neuronal calcium buffering. Transient elevations in synaptic calcium are required 
for maturation and maintenance of synapses, but prolonged increases in cytosolic calcium levels 
can lead to excitotoxic injury. Excitotoxic stimuli induces excessive mitochondrial calcium 
influx, leading to dissipation of mitochondrial membrane potential, perturbed mitochondrial 
respiration, and increased reactive oxygen species production (reviewed in [229]). PINK1, in 
cooperation with PKA, regulates extrusion of calcium from the mitochondria via the Na+/Ca2+ 
exchanger to protect against mitochondria calcium overload [87]. As synapse loss is an early 
event in excitotoxic injury, deregulation of the primary mechanism of mitochondrial calcium 
efflux may be partially responsible for reduced synaptic marker expression in PINK1 KO mice. 
PINK1 deficiency induces accumulation of LC3-positive puncta in neuronal cells  (Fig. 
26, [117, 118]). Recently, dendritic spine pruning defects were linked to deficient neuronal 
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autophagy in a mouse model of autism [230]. Similar impairments in synapse elimination were 
observed in mice lacking expression of the essential autophagy protein Atg7. Therefore, it is 
conceivable that the reverse is true in PINK1 KO mice, and overactivation of autophagy leads to 
unnecessary elimination of functional synapses. Further, chemical induction of autophagy 
depresses evoked dopamine release [231], a phenotype also observed in the striatum of PINK1 
KO and +/- mice [113, 114]. Thus, chronic autophagic stress may contribute to the loss of 
synapses in PINK KO mice. 
These three proposed mechanisms are by no means exclusive. It is entirely conceivable 
that PINK1 finely tunes transient elevations in synaptic calcium by promoting calcium entry 
through CaV2.2 or NMDAR and calcium extrusion from the mitochondria [87].  Loss of PINK1 
would perturb this tightly regulated process leading to depolarization of mitochondria, and 
eventually, impaired mitochondrial function. Diminished intracellular levels of ATP may then 
activate AMP-activated protein kinase (AMPK), which is known to promote autophagy 
induction [232].  
5.3 PINK1 AND VCP COOPERATE TO REGULATE AUTOPHAGY 
Phosphorylation of LC3 at Ser12 by PKA inhibits its incorporation into autophagosomes [199]. 
PINK1 overexpressing neuronal cell lines are resistant to accumulation of LC3 puncta induced 
by treatment with the PD-associated toxin 6-hydroxydopamine [117]. Additionally, PINK1 
deficiency promotes LC3 lipidation in dopaminergic neuronal cell lines [117, 118] and the 
striatum of mice injected with PINK1 shRNA lentivirus [118]. PKA inhibition reverses the 
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rescue of neurite length in PINK1 deficient cells by overexpression of VCP (Fig. 13C). Given 
that VCP overexpression also prevents accumulation of autophagosomes induce by PINK1 
knockdown (Fig. 26), the contribution of PKA phosphorylated LC3 to the regulation of 
autophagy by PINK1 was explored. Contrary to expectations, PINK1 overexpression caused a 
dramatic reduction in density of the ~20 kDa phospho-LC3 (Ser12) band (Fig 29). This decrease 
was accompanied by increased density of a pLC3 immunoreactive band above 250 kDa.  Further, 
intensity of the phospho-LC3 immunoreactive band above 250 kDa is reduced by treatment with 
a PKA inhibitor, whereas the ~20 kDa band remains unaffected. This finding may suggest that 
PINK1 promotes the association of PKA phosphorylated LC3 with an unidentified binding 
partner. Diffusion dynamics suggest that LC3 does not exist as a freely diffusing monomer in the 
soluble fraction, and is more likely to be incorporated into macromolecular complexes [233, 
234]. It is possible that phosphorylation of LC3 at Ser12 augments its incorporation into one of 
these complexes, thereby limiting its availability for autophagy induction. 
Perhaps the most surprising finding of this project was that overexpression of PINK1 
promotes accumulation of high-molecular weight ubiquitination products (Fig. 30A-C). One 
straightforward explanation for this phenomenon is that PINK1 may modulate free ubiquitin 
levels. Increased levels of monomeric ubiquitin may facilitate accumulation of high molecular 
weight ubiquitination products by overcoming the obstacle of substrate availability. At least in 
HEK293 cells, free ubiquitin levels were unaltered by overexpression of WT- or PD-associated 
PINK1 mutants (Fig. 30C). Thus, other mechanisms that promote the accumulation of ubiquitin 
conjugates are more likely. 
Another reasonable hypothesis is that PINK1 suppresses proteasomal degradation of 
poly-ubiquitinated proteins. The majority of cytosolic proteins are targeted for degradation by 
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the ubiquitin proteasome system (UPS) [235]. Disruption of this degradation pathway results in 
the accumulation of ubiquitin conjugates. Impaired UPS function has been linked to PD, 
Alzheimer’s disease, Hungtington’s disease, and amyotrophic lateral sclerosis (reviewed in 
[236]). However, multiple pieces of evidence indicate that PINK1 is unlikely to inhibit global 
function of the proteasome. First, inhibition of the proteasome with MG132 does not 
differentially affect accumulation of ubiquitin conjugates in control and PINK1 overexpressing 
cells (Fig. 30B). If PINK1 already inhibited proteasomal activity, a more robust buildup of 
ubiquitin conjugates would be anticipated following treatment with MG132. One possibility is 
that PINK1 alone is sufficient to completely inhibit proteasome activity, so treatment with 
MG132 has no additive effect. This is unlikely, as overexpression of PINK1 in neuronal cells 
does not cause an accumulation of ubiquitin conjugates in untreated cells. It is possible that the 
MG132 treatment paradigm used here completely inhibits the proteasome, masking any effect of 
PINK1 overexpression. To substantiate or refute this hypothesis, a MG132 dose curve could be 
employed to test sensitivity of PINK1 overexpressing cells to ubiquitin accumulation induced by 
proteasomal inhibition. It is widely accepted that proteasome inhibition promotes activation of 
autophagy (reviewed in [237]). The general consensus is that autophagy likely acts as a backup 
mechanism in this context in order to maintain proteostasis while proteasomal degradation is 
overburdened. Incongruously, overexpression of PINK1 reduces LC3 lipidation following 
treatment with a VCP inhibitor (Fig. 25A-D). It seems more probable that PINK1 only interferes 
with the proteasomal degradation of a subset of VCP client proteins. PINK1 pulls down the ND1 
domain of VCP with the greatest efficiency, a construct containing the N-domain of VCP, which 
is the primary site of cofactor binding [126]. Thus, it is possible that PINK1 modulates the 
association of VCP with some of these cofactors, but further investigation will be required to 
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determine whether PINK1 overexpression substantially alters the VCP interactome and whether 
any observed changes may contribute to ubiquitin accumulation.  
Alternatively, PINK1 may facilitate cargo loading of autophagosomes. PINK1 
phosphorylates ubiquitin (Ser65) at the mitochondrial surface to promote autophagic clearance of 
mitochondria [4, 100, 101]. Additionally, phosphorylated ubiquitin (Ser65) has been reported to 
localize to the periphery of Lewy bodies in the brains of PD patients [121]. One potential 
interpretation of these findings is that ubiquitin phosphorylated by PINK1 acts as a signal for 
expedited clearance of cargo by selective autophagy. Deficient cargo loading was recently 
identified in multiple models of Huntington’s disease [238]. While formation and clearance of 
autophagic vacuoles is largely intact, the polyubiquitinated content of autophagosomes was 
dramatically reduced in cells bearing a polyglutamine expansion in the mouse homolog of the 
huntingtin gene. It is conceivable that inefficient degradation of substrates through this 
mechanism may lead to accumulation of autophagosomes, either by delayed loading or 
compensatory upregulation of autophagy induction.  
This proposed role for PINK1 in cargo loading of autophagosomes seems to better fit the 
data generated during the course of this project. Here we reported that PINK1 overexpression 
prevented the accumulation of lipidated LC3 induced by VCP inhibition (Fig. 25A-B). VCP 
inhibition impairs maturation of autophagosomes containing ubiquitinated substrates [133]. If 
PINK1 fosters sequestration of misfolded proteins and damaged organelles, the positive feedback 
loop stimulated by inefficient autophagic clearance could be disrupted despite partial blockage of 
autophagosome maturation. It follows that PINK1 knockdown cells would be more sensitive to 
autophagosome accumulation induced by VCP inhibition (Fig. 25C) if multiple steps of the 
process are impaired. Further, overexpression of VCP may compensate for uneconomical 
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loading of a cargo induced by PINK1 deficiency by expediting autophagosome maturation. 
Introduction of PINK1 into HEK293 cells, given their high level of exogenous protein 
expression, may exceed the capacity of the cell for autophagic degradation of targeted cargo. 
This speculation is consistent with data demonstrating less robust overexpression of PINK1 does 
not cause accrual of polyubiquitinated products in SH-SY5Y cells (Fig. 30B). In this 
experimental paradigm, the additional stress of VCP inhibition was required to promote 
accumulation of high molecular weight ubiquitin conjugates. It is also possible that this 
discrepancy is a cell-type (neuronal vs. non-neuronal) specific effect rather than a result of 
increased expression.  
The mechanism by which the phosphorylation of ubiquitin by PINK1 promotes 
recruitment of parkin has not yet been described in the literature. One potential explanation is 
that phosphorylation at Ser65 stabilizes ubiquitin chains, increasing the likelihood that they will 
bind to parkin. The ability of multiple deubiquitinating enzymes, including ataxin-3, to 
hydrolyze polyubiquitin chains phosphorylated at Ser65 is impaired in vitro [239]. Glutamine 
expansions in the gene encoding for ataxin-3 are the genetic cause of Machado–Joseph disease, a 
spinal-cerebellar ataxia. Like many other neurodegenerative diseases, large proteinaceous 
inclusions are observed in the brains of Machado-Joseph disease patients [240, 241]. There is an 
expanding body of evidence that ataxin-3 is both a component of these aggregates, and involved 
in autophagic clearance of aggregated proteins. Ataxin-3 facilitates delivery of ubiquintated 
proteins to aggresomes targeted for autophagic degradation by trimming K63-linked ubiquitin 
chains [242]. Subsequently, ataxin-3 edited chains promote the association of aggregated 
proteins with histone deacetylase 6 [243], enabling delivery to aggresomes through dynein 
mediated trafficking [244]. Interestingly, ataxin-3 is a VCP binding partner, and this association 
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augments the hydrolytic activity of ataxin-3 [245]. Therefore, inhibition of VCP may enhance 
the accumulation of high-molecular weight conjugates by disabling ataxin-3 processing of 
PINK1 phosphorylated ubiquitin chains.  
 Another perplexing finding reported here is that PINK1 overexpression promotes PARP1 
cleavage following treatment with a VCP inhibitor (Fig. 30B). This was particularly surprising 
given that PINK1 protects against apoptosis induced by oxidative stress [76], proteasomal 
inhibition [55], mitochondrial depolarization [77], and ETC complex I inhibition [78]. Though 
an unanticipated result, it is clear that PINK1 overexpression modulates the mechanism through 
which DBeQ causes toxicity. Inhibition of VCP results in the accumulation of nuclear Lys48-
conjugated ubiquitination products that leads to persistence of double-stranded breaks in DNA 
[246]. PARP1 plays a pivotal role in detection and repair of damaged DNA, and its activity is 
modulated in apoptosis, necroptosis, parthanatos, and autophagic cell death (reviewed in [247]). 
While the PARP1 cleavage observed in PINK1 overexpressing cells is characteristic of apoptotic 
cell death, increased expression of full-length PARP1 in control cells is more consistent with 
autophagy activation and necroptosis induced by DNA damage [248, 249]. Cells that depend on 
aerobic glycolysis for ATP production are more susceptible to necroptosis induced by DNA 
damage, whereas cells that are able to produce energy through oxidative phosphorylation are 
relatively resistant to this mode of cell death [250]. PINK1 promotes electron transport chain 
complex I [82-85, 251], and II [82, 84, 85] linked respiration. Though further study will be 
required, it is possible that this alteration in response to VCP inhibition may be due to the 
increased capacity of cells overexpressing PINK1 for mitochondrial respiration, rather than 
modulation of the primary insult.  
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5.4 LIMITATIONS TO DATA INTERPRETATION 
Several pieces of preliminary data were included in this dissertation that provided rationale for 
subsequent experiments. In some studies, experiments were also performed with PINK1 
constructs with different tags to ensure that results were tag-independent (Fig. 12B), or to 
validate findings by others that had worked on the project (Fig. 9A-B). Certainly, these 
experiments and the other preliminary studies included here need to be repeated to meet the 
rigors of peer-review for publication and would provide meaningful support for hypotheses 
generated during the course of this project.  
 Tagged LC3, particularly LC3-GFP, has been shown to aggregate in an autophagy-
independent manner [252]. Additionally, lipidated LC3 can been observed in a number of 
genetically modified cell lines, even though autophagy is almost completely inhibited [253]. For 
these reasons, though LC3 lipidation and puncta formation are the gold standard for monitoring 
autophagy regulation, measures that provide additional information about observed impairments 
and confirmation of LC3 findings should be analyzed. In initial experiments analyzing the effects 
of VCP inhibition on autophagy in PINK1 overexpressing or knockdown cells, expression level 
of another autophagic marker (p62) was also probed. The p62 data was not included here 
because the results were highly variable between experiments, making the findings impossible to 
interpret. Biochemical experiments employing pharmacologic and/or genetic manipulators of 
autophagy induction and autophagic flux and electron microscopy studies would improve 
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6.0  FUTURE DIRECTIONS 
6.1 PINK1 AND SYNAPTIC CALCIUM 
Phosphorylation of CRMP2 at Ser522 promotes its association with N-type voltage gated 
calcium channels (CaV2.2) [194]. This association augments CaV2.2 current and 
neurotransmitter release into the synapse [191, 192, 194]. Deficient evoked catecholamine 
release and LTP failure that could be rescued by chemically induced dopamine release have been 
reported for heterozygous PINK1 KO mice [114].  Considered in connection with the findings 
reported here, CaV2.2 is a promising, potential downstream effector of PINK1 signaling.  
Calcium influx in the axon terminal and dendritic spines of PINK1 knockout and 
overexpressing neurons could be monitored with a genetically encoded calcium indicator 
(GCaMP) [254], or a cell-permeable, ratiometric calcium binding dye (Fura2-AM). The CaV2.2 
inhibitor, ω-conotoxin could be used to evaluate the contribution of N-type voltage gated 
calcium channels to calcium entry in these neurons. A peptide derived from the CaV2.2 binding 
domain of CRMP2 fused to an N-terminal myristate group (myr-tat-CBD3) disrupts the 
interaction between CRMP2 and CaV2.2 [191, 223, 225]. This reagent could be used to more 
directly assess the role of the CRMP2-CaV2.2 interaction in calcium influx in PINK1 
overexpressing or knockdown neurons. The contribution of CaV2.2 mediated calcium entry to 
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regulation of dendritic spine density and dendrite arborization could also be evaluated in PINK1 
overexpressing and knockout neurons exposed to ω-conotoxin or myr-tat-CBD3. 
Synaptic maturation coincides with increasing somatodendritic localization of CaV2.2 
[226]. Additionally, dissociation of the interaction between CRMP2 and CaV2.2 perturbs 
intracellular delivery of CaV2.2 to the synaptic membrane [225]. Thus, intracellular distribution 
of CaV2.2 and its co-localization with CRMP2 could be investigated in PINK1 knockout and 
overexpressing neurons. Further, the dynamics of somatodendritic CaV2.2 localization and 
synaptic maturation in PINK1 overexpressing neurons could be monitored to determine how 
closely they coincide.  
CRMP2 also binds to the NR2B subunit of the NMDA receptor, another regulator of 
calcium entry in dendritic spines [255]. Through regulation of synaptic calcium entry, NR2B 
plays a key role in LTP [256, 257] and spine maturation [224]. Additionally, calcium influx 
through the NMDAR is potentiated by PKA signaling [222]. Thus, the contribution of NMDAR 
activation to dendritic calcium influx, spinogenesis, and arborization could be evaluated in 
PINK1 overexpressing and knockdown neurons treated with the NMDAR inhibitor memantine 
and/or the PKA inhibitor H89. Disruption of the CRMP2-NR2B interaction reduces NMDAR 
surface expression [223]. Therefore, distribution of NMDAR and its co-localization with 
CRMP2 could also be evaluated in PINK1 overexpressing and knockout neurons. 
 As mentioned above, disruption of the association between CRMP2 and NR2B or 
CaV2.2 reduces their surface expression. Though most recognized for its role in extracting 
proteins from organellar membranes, VCP also targets target mono-ubiquitinated caveolin-1 to 
multiple vesicular bodies for degradation through endosomal sorting [134, 258]. NR2B [259] and 
CaV2.2 [260] are also endocytosed and targeted for lysosomal or proteasomal degradation 
 
 
  96 
respectively. Given that CRMP2 regulates endosomal transport [184], it is possible that PINK1-
VCP and CRMP2 cooperate to regulate NR2B and CaV2.2 degradation. To test this hypothesis, 
NR2B and CaV2.2 expression could be assessed in PINK1 overexpressing neuronal cells 
following transient knockdown or pharmacological inhibition of VCP. Cumulatively, these 
studies could determine whether synaptic calcium influx, through previously identified CRMP2 
interacting proteins, contributes to PINK1-VCP regulation of neuronal morphology and 
spinogenesis. 
6.2 REGULATION OF CRMP2 PHOSPHORYLATION BY PINK1 
CRMP2 activity is tightly regulated by post-translation modifications [178]. Based on the 
findings of this project, PINK1 will be added to the growing list of proteins that regulate CRMP2 
phosphorylation. Evidence shown here, when considered in context with the known dendritic 
functions of phospho-CRMP2 (Ser522), suggests that the effects of PINK1 on spine maturation 
and neuronal morphology are mediated through CRMP2. To directly test this hypothesis, WT- 
and a non-phosphorylatable CRMP2 (S522A) construct could be co-expressed with PINK1 in 
neurons. Spine number and morphology, along with dendritic arborization could be analyzed in 
these neurons.  
CRMP2 was first identified as the mediator of axonal retraction and growth cone collapse 
induced by secretion of the neuronal guidance molecule semaphorin 3A. Conversely, semaphorin 
3A signaling increases dendritic spine density and promotes activity-dependent dendritic 
arborization [261, 262]. Cdk5 phosphorylates CRMP2 at Ser522 following activation of 
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semaphorin 3A signaling. Phosphorylation of CRMP2 at Ser522 is a crucial regulator of 
dendritic field organization [196] and spine maintenance [195]. Cumulatively, these studies 
indicate that phosphorylation of CRMP2 at Ser522 likely has divergent effects in dendritic and 
axonal compartments. To begin to investigate this in the context of PINK1, localization of total- 
and phospho-CRMP2 (Ser522) could be evaluated in PINK1 overexpressing and knockout 
neurons.  
 It will also be important to determine whether PINK1 regulates the activity of kinases and 
phosphatases known to modulate the phosphorylation status of CRMP2. Interestingly, 
overexpression of G309D- but not WT-PINK1 promotes hyperphosphorylation of tau, another 
Cdk5 and GSK3-β target [209]. This accumulation of highly phosphorylated tau was largely 
attributed to over-activation of GSK3-β. To determine whether GSK3-β signaling also 
contributes to the phenotypes observed above, levels of GSK3-β phosphorylated at its 
inactivation site (Ser9) could be assayed in the ventral midbrain of WT and PINK1 KO mice, 
and neuronal cells overexpressing WT- and PD-associated PINK1 mutants. Additionally, these 
lysates could be probed for CRMP2 at known GSK3-β phosphorylation sites (Thr509 and 
Thr514). Protein phosphatase 2A (PP2A) also regulates CRMP2 phosphorylation [175, 212-
214]. Intriguingly, the Cdk5 phosphorylation site (Ser522) of CRMP2 is relatively resistant to 
dephosphorylation by PP2A [212]. PINK1 knockdown inhibits PP2A activation [118] and 
PINK1-GFP pulled down the catalytic subunit of PP2A in our proteomic screen of PINK1 
interacting proteins (Data not shown). To determine whether PINK1 contributes to regulation of 
PP2A activity, levels of phosphorylation at its inactivating site (Tyr307) could be assessed in the 
ventral midbrain of WT and PINK1 KO mice and neuronal cell lines expressing WT- or PD-
associated PINK1 mutants. Additionally, commercially available kits could be used as a direct 
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measure of PP2A activity on lysates from neuronal cells expressing WT- or PD-associated 
PINK1. The effect of GSK3-β (6BIO) and PP2A (okadaic acid) inhibition on isoelectric focusing 
of CRMP2 in PINK1 overexpressing neuronal cells and knockout neurons could also be 
assessed.  
Data shown here identify Ser522 as a PINK1 regulated phosphorylation site of CRMP, 
but it remains unknown whether PINK1 can directly phosphorylate this site. Further, the 
intensities of multiple spots are altered by loss or overexpression of PINK1, leaving open the 
possibility that PINK1 regulates more than one phosphorylation site. In vitro kinase assays 
coupled to mass spectrometric analysis could be employed to determine whether PINK1 can 
directly phosphorylate CRMP2 at Ser522 or other residues. Isoelectric focusing of CRMP2 and 
levels of CRMP2 phosphorylated at Ser522 could be analyzed in these lysates. Finally, 
phosphorylation of CRMP2 could be assessed in cells expressing These proposed studies would 
delineate the mechanism by which PINK1 modulates CRMP2 phosphorylation and regulates 
neuronal morphology.  
6.3 PINK1 AND CRMP2 IN REGULATION OF MITOCHONDRIAL TRAFFICKING 
Cytosolic PINK1 promotes anterograde trafficking of mitochondria in the dendrites [110] and 
inhibit retrograde transport of axonal mitochondrial [61]. Similarly, CRMP2 associates with 
kinesin to facilitate anterograde trafficking [182, 186] and dynein to inhibit retrograde transport 
[183]. It is possible that processed PINK1 modulates the phosphorylation status of Miro/Milton 
to regulate mitochondrial trafficking, as full-length PINK1 does following chemical 
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depolarization of mitochondria [108, 109]. However, given the interaction between PINK1 and 
CRMP2 reported here, it is reasonable to hypothesize that CRMP2 is a downstream mediator of 
PINK1 regulated mitochondrial trafficking.  
To explore this possibility, dendritic mitochondrial content and distribution could be 
evaluated in primary neurons co-expressing ΔN-PINK1 and WT- or S522A-CRMP2. Particular 
attention should be paid to the distribution of mitochondria in dendritic spines, given the 
importance of the process to synapse maturation and maintenance [263]. Additionally, WAVE1, 
a protein whose axonal trafficking is regulated by CRMP2 [182], promotes activity-dependent 
trafficking of mitochondria into dendritic filopodia and spines [264]. Thus, live cell imaging 
could be employed to monitor the dynamics of mitochondrial entry into dendritic spines in 
PINK1 overexpressing and knockdown neurons treated with NMDAR agonists or inhibitors. 
Similar experiments could be conducted in neurons expressing WT- or S522A-CRMP2. More 
comprehensive measures of mitochondrial trafficking, such as the mobile fraction (fraction of 
total mitochondria that move during the course of the experiment), ratio of mitochondria moving 
anterograde versus retrograde, and mitochondrial velocity could also be assessed. These 
experiments would help to clarify whether the effects of cytosolic PINK1 on mitochondrial 
trafficking are mediated through CRMP2. 
6.4 REGULATION OF UBIQUITINATED PROTEINS BY PINK1-VCP  
Perhaps the most surprising finding of this project was that cytosolic PINK1 overexpression 
induces a dramatic accumulation of high molecular weight ubiquitination products in HEK293 
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cells. Interestingly, PINK1 overexpression alone did not cause this accrual in a neuronal cell line, 
but it was observed following treatment with a VCP inhibitor. Full-length PINK1 phosphorylates 
ubiquitin on the outer membrane of chemically depolarized mitochondria to activate parkin and 
promote mitophagy [4, 100, 101]. It remains unknown whether cytosolic PINK1 is also able to 
phosphorylate ubiquitin. To investigate this, levels of ubiquitin phosphorylated at Ser65 could be 
assessed in cells expressing ΔN-PINK1 and OMM-PINK1. Additionally, levels of phospho-
ubiquitin (Ser65) could be evaluated in PINK1 overexpressing neuronal cells treated with a panel 
of cellular stressors, including a VCP inhibitor. Data from these experiments would provide 
insight into the types of stimuli that promote phosphorylation of ubiquitin by PINK1 in neuronal 
cells.  
While the phosphorylation of ubiquitin by PINK1 at the mitochondrial surface promotes 
mitophagy [4, 100, 101], it is unclear whether Ser65 phosphorylation universally fosters 
autophagic degradation. To study this in the context of PINK1-VCP regulated autophagy, LC3 
lipidation, puncta formation, and ubiquitination could be monitored in the PINK1 stable 
overexpression cell line co-transfected with WT- or a non-phosphorylatable ubiquitin mutant 
(S65A) following treatment with a VCP inhibitor. Additionally, WT- and S65A-ubiquitin could 
be immunoprecipitated from PINK1 overexpressing cells treated with a VCP inhibitor. The 
ability of these constructs to co-immunoprecipitate known autophagy receptors (p62, OPTN, 
NBR1, TOLLIP, Cue5) should also be analyzed.  
Recently, it was reported that phosphorylation of ubiquitin at Ser65 impairs the 
hydrolytic activity of multiple deubiquitinating enzymes in vitro, including ataxin-3 [239]. VCP 
interacts with and promotes the activity of ataxin-3 [245]. Given that inhibition of VCP is 
required for accumulation of polyubiquitinated products in PINK1 overexpressing neuronal cells, 
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it is possible that inhibition of ataxin-3 activity contributes to this phenotype. To test this 
hypothesis, the PINK1 overexpressing neuronal cell line could be transfected with ataxin-3 
siRNA and the levels of ubiquitin in the resulting lysates assessed. If ataxin-3 inactivation is a 
major contributor to this phenotype, the results from this experiment would be expected to 
closely parallel those found in Figure 30B.  
Polyubiquitin chains have distinct functions depending on their linkage. For example, 
proteins destined for proteasomal degradation are often ubiquitinated with Lys48 linked chains, 
but Lys48 linkages promote the segregase activity of VCP [265]. Also potentially relevant to this 
project, Lys63 polyubiquitination promotes the selective clearance of inclusions through 
autophagic degradation [266]. Determining whether PINK1 preferentially promotes 
accumulation of ubiquitin chains with specific linkages may provide insight into biological 
consequence of this accrual. To investigate this possibility, linkage-specific polyubiquitin 
antibodies could be used to assess levels of the three most predominant linkages of polyubiquitin 
chains (Lys11, Lys48, and Lys63) in neuronal cells overexpressing PINK1. Levels of these 
polyubiquitin chains could also be assessed in cells overexpressing PINK1 following treatment 
with a VCP inhibitor, to determine whether VCP activity contributes to any observed 
differences. These proposed experiments build on the findings reported here to help elucidate the 
mechanism through which PINK1 and VCP cooperate to promote accumulation of 
polyubiquitination products.     
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6.5 CRMP2 PHOSPHORYLATION IN PD, IBMPFD, AND NEUROFIBROMATOSIS 
In this project, we demonstrated that WT-PINK1 co-IPs CRMP2 and regulates its 
phosphorylation. Additionally, two PD-associated mutants were shown to pull down less 
endogenous VCP than WT-PINK1. Future studies should evaluate whether CRMP2 binding is 
reduced for any of these mutations. The possibility that PD-associated PINK1 mutants disrupt 
the interaction between NF1 and VCP or CRMP2 could also be investigated. Additionally, 
phosphorylation at Ser522 and isoelectric focusing of CRMP2 should be evaluated in neuronal 
cells expressing PD-associated PINK1 mutations.   
Impaired dendritic spine maturation and/or maintenance have been reported in genetic 
[217, 267, 268] and toxin [218, 219, 269, 270] animal models of PD. It will be important to 
determine whether altered CRMP2 phosphorylation contributes to this pathology in response to a 
broad spectrum of parkinsonian injury, or if it is only observed in PINK1 models. To examine 
this, phosphorylation of CRMP2 could be evaluated in genetic (leucine-rich repeat kinase, 
parkin) and toxin (6-OHDA, MPTP) cell culture and/or animal models of PD. If altered CRMP2 
phosphorylation is consistently observed, post-mortem samples from the individuals with 
idiopathic PD could also be examined. 
Knockdown of VCP and NF1 impaired PINK1 induced neurite outgrowth and dendritic 
arborization. Therefore, it is reasonable to hypothesize that VCP or NF1 pathogenic mutants that 
disrupt associations between components of the PINK1-VCP-NF1-CRMP2 signaling hub may 
also perturb regulation of CRMP2 phosphorylation by PINK1. Initially, CRMP2 phosphorylation 
at Ser522 and isoelectric focusing of CRMP2 could be evaluated in neuronal cells expressing 
pathogenic VCP and NF1 mutants known to disrupt the NF1-VCP interaction. If differences are 
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observed, a panel of pathogenic NF1 and VCP mutants could be generated or obtained. The 
capacity of these mutants to disrupt interactions between PINK1 and VCP, VCP and NF1, NF1 
and CRMP2, or CRMP2 and PINK1 could then be assessed. Phosphorylation of CRMP2 could 
then be monitored in cells expressing mutants that dissociate physical associations between 
members of the PINK1-VCP-NF1-CRMP2 signaling pathway. CRMP2 phosphorylation could 
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7.0  SUMMARY 
The results presented here provide the first evidence that PINK1 physically associates with the 
cytosolic AAA+ ATPase VCP. PINK1 induced neurite outgrowth and dendritic arborization is 
impaired following disruption of this interaction by expression of the PINK1-binding domain of 
VCP, VCP knockdown, or expression of PD-associated PINK1 mutants. The ability of PINK1 to 
promote dendritic complexity is also contingent upon expression of NF1, a protein known to 
interact with VCP to promote spinogenesis [152]. Additionally, PINK1 was found to associate 
with another NF1 interacting protein, CRMP2, and regulate its phosphorylation at Ser522. 
Previous work has demonstrated that phosphorylation of CRMP2 at Ser522 is required for 
dendritic spine maintenance [195]. Consistent with this finding, reduced levels of phosphorylated 
CRMP2 and decreased expression of synaptic markers were observed in the ventral midbrain of 
PINK1 KO mice. Moreover, overexpression of PINK1 promotes maturation of dendritic spines 
in mouse cortical neurons. In summary, this project identified PINK1-VCP-NF1-CRMP2 as 
components of a signaling hub that regulates dendritic morphology and synaptic maturation and 
maintenance.  
PINK1 and VCP were also shown to co-regulate autophagy. Expression of PINK1 
modulates the sensitivity of neuronal and non-neuronal cells to autophagosome accumulation 
induced by VCP inhibition. Further, overexpression of VCP prevented accrual of LC3 puncta in 
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PINK1 deficient cells. Knockdown of an essential autophagy protein did not cause further 
extension of neurites, but it did abrogate the difference in neurite length between control and 
PINK1 overexpressing cells. Autophagy induced by expression of a LC3 mutant impaired the 
PINK1 induced neurite extension. These findings suggest that inhibition of autophagosome 
accumulation is not the sole mechanism of PINK1 induced neurite outgrowth, but is likely a 
contributing factor. Finally, inhibition of VCP promotes accumulation of high molecular weight 
ubiquitination products. The role of autophagy in this buildup is currently unknown. 
This project has found that the PINK1-VCP interaction is important for dendritic 
arborization, synaptic maturation and maintenance, and autophagy regulation. Future studies will 
focus on elucidating the mechanisms by which PINK1 promotes accumulation of ubiquitination 
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Figure 32: Proposed model of PINK1-VCP-NF1-CRMP2 signaling in regulation of neuronal 
morphology. This study identified two novel PINK1 interaction partners, VCP and CRMP2. The 
data shown here demonstrate that PINK1 and VCP cooperate to suppress autophagosome 
accumulation, with mild effects on neurite length. VCP and CRMP2 also share another binding 
partner, NF1. PINK1 and NF1 co-regulate CRMP2 phosphorylation at Ser522 to promote 
dendritic spine maturation and maintenance. Further, VCP and NF1 were shown to act 
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